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ABSTRACT
This study has pharmacologically characterised the role of intracellular Ca2+ 
release and Ca2+ influx, as well as the signal transduction pathways involved in 
C5a- and fMLP-induced activation of human eosinophils.
C5a and fMLP caused concentration-dependent increases in [Ca2+]if leukotriene 
C4 (LTC4), superoxide (O2 ) and ECP release. C5a caused the release of Ca2+ 
from intracellular stores, via inositol 1,4,5-trisphosphate formation, as well as 
Ca2+ influx. EGTA markedly inhibited both C5a- and fMLP-induced 0~2 and LTC4 
generation, suggesting a requirement for extracellular Ca2+ for these responses.
Ni2+ and SK&F 96365, which block receptor-mediated Ca2+ entry (RMCE), but 
not the voltage-operated Ca2+ channel (VOC) blocker, nifedipine, caused 
marked inhibition of the C5a-induced Mn2+ influx response. Furthermore, SK&F 
96365 and Ni2+, but not nifedipine, inhibited both C5a- and fMLP-induced Ojand 
LTC4 production. In contrast, ECP release in response to fMLP did not appear 
to require Ca2+ influx and C5a was only partially dependent upon RMCE. 
However, all of the responses appeared to be dependent upon tyrosine kinase 
activation, as they were inhibited by the erbstatin analogue.
Finally, RMCE is probably regulated by depletion of intracellular Ca2+ stores, as 
C5a-induced release of intracellular Ca2+ correlated closely with Ca2+ (Mn2+) 
influx. Furthermore, eosinophils possess such a mechanism for regulating Ca2+ 
influx, as the endomembrane Ca2+/Mg2+-ATPase inhibitor, thapsigargin 
stimulated both Ca2+ and Mn2+ influx responses, as well as LTC4 release.
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1.1 INTRODUCTION
Eosinophils are polymorphonuclear leukocytes, which are normally present in 
relatively low numbers (<6 x 108/L) in peripheral blood (Spry, 1988). They were 
first identified by Paul Ehrlich in 1879, when he discovered that eosinophils could 
be stained using the negatively charged dye, eosin (Ehrlich, 1879a). It is now 
known that this is due to eosin binding to the highly cationic proteins present in 
eosinophil granules. He also proposed that eosinophils were derived from the 
bone marrow (Ehrlich, 1879b) and that they exerted their actions in tissues 
(Ehrlich and Lazarus, 1900).
1.1 Eosinophil morphology
Eosinophils are distinguished by a bilobed nucleus and by their characteristic 
granules (figure 1). They are usually oval or spherical, with a diameter of 
approximately 8pm and a volume of 275fl (Sokol et al., 1987). However, they 
have been seen to develop pseudopods in human blood, sputum, bone marrow 
and nasal smears and are termed 'medusa cells' when this happens (Hanker et 
al., 1981). The nucleus occupies 20% of the cell volume and the specific 
granules occupy 20% of the cytoplasm (Sokol et al., 1987).
Primary, secondary and small granules are present in mature eosinophils. 
Primary granules are formed during the promyelocyte stage of eosinophil 
development. They are round, uniformly electron dense and contain 
lysophosphatase, which crystallises to form Charcot-Leyden crystals (Dvorak et 








Diagram showing the morphology of the human eosinophil.
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Eosinophil specific or secondary granules have an electron-dense crystalloid 
core within a less electron-dense matrix. They are present in mature eosinophils 
and may develop from large primary lysosomal granules, which are formed in the 
promyelocyte stage of development (Bainton and Farquhar, 1970). Secondary 
granules contain basic proteins (major basic protein (MBP), eosinophil cationic 
protein (ECP) and eosinophil-derived neurotoxin (EDN)), hydrolases 
(collagenase and p-glucuronidase) and eosinophil peroxidase (EPO). MBP is 
stored in the crystalloid core of the granule, with the other basic proteins and 
hydrolytic enzymes stored in the surrounding matrix (Kroegel et al., 1994).
Currently little is known about small granules, which are present in mature 
eosinophils, other than the fact that they contain arylsulphatase B and acid 
phosphatase (Gleich et al., 1993).
Eosinophils also contain lipid bodies, which are non-membrane-bound lipid-rich 
inclusions in the cytoplasm. Their numbers increase in activated eosinophils and 
they have been shown to incorporate 3H-arachidonate and appear to function as 
intracellular sites of arachidonic acid storage and metabolism (Weller and 
Dvorak, 1985).
1.2 Eosinophil surface markers and receptors
Eosinophils have many surface markers, including binding sites for 
immunoglobulins, lipid mediators, complement proteins, cytokines and adhesion 
molecules (Kroegel et al., 1992). In common with other circulating white blood 
cells, eosinophils express surface class I human leukocyte antigen (HLA) and
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the common leukocyte antigen (CD45) (Hartnell eta!., 1990). They also express 
Immunoglobulin (Ig) E receptors, similar but not identical to the FceRII (CD23) 
receptors on lymphocytes and monocytes (Grangette etal., 1989), as well as IgA 
receptors (Capron et al., 1989). Binding of IgE leads to release of EPO and 
generation of platelet-activating factor (PAF), but does not cause ECP release 
(Capron etal., 1989). In contrast, IgA challenge causes significant degranulation 
of eosinophils, including release of EPO and ECP (Capron et al., 1989; 
Abu-Ghazaleh etal., 1989). IgG receptor expression is limited on normal human 
eosinophils and IgM receptors are absent. The only IgG receptor that 
eosinophils express is FcyRII, whereas neutrophils express FcvRII and FcyRIII 
(CD16) and monocytes express FcyRI and FcyRII (Kroegel et al., 1994). This 
important difference in IgG receptor expression between neutrophils and 
eosinophils has been used to great advantage in the separation of these two cell 
types, using an immunomagnetictechnique (Hansel etal., 1991).
Eosinophils also express a number of adhesion molecules including selectins, 
pr integrins (very late antigen (VLA)) and p2"*nte9r*ns (the a-chains CD11a, 
CD11b and CD11c with their common p-chain CD18) (Hansel and Walker,
1992). Cytokine Binding sites for cytokines, including interleukin- (IL-) 3, IL-5 
and granulocyte/macrophage colony-stimulating factor (GM-CSF), are also 
present on human eosinophils (Lopez etal., 1991).
Eosinophils also possess surface receptors for complement factors (including 
C3a and C5a), chemotactic peptides (fMLP), prostaglandins, leukotrienes (LTB4) 
histamine and PAF (Goers etal., 1984; Gerard etal., 1989; Raible etal., 1992;
Fukuda etal., 1992). The effects of these agents are dramatically enhanced if 
the eosinophils have undergone prior exposure to PAF (Zoratti et al., 1992) or 
the cytokines IL-3, IL-5 or GM-CSF (Bourgoin etal., 1991; Takafuji etal., 1991). 
This process of sensitisation to a subsequent activating stimulus is known as 
'priming' (Bruijnzeel etal., 1992).
1.3 Role of the eosinophil in health and disease
Eosinophils were originally believed to be involved in removal and detoxification 
of the products from tissue reactions in allergic and granulomatous diseases 
(Spry, 1988). By the 1960s this view had adapted to incorporate the notion that 
eosinophils may inhibit the functions of mast cells by degrading histamine, as 
well as having a role in antigen presentation for antibody synthesis (Archer, 
1968; Speirs, 1958). In the 1970s, it became clear that eosinophils also had a 
major role in the defence against parasitic infection. Butterworth et al. (1975) 
showed eosinophil-dependent killing of the schistosomula of Schistosoma 
Mansonii and later showed that this was mediated via the release of major basic 
protein (MBP) from eosinophil granules (Butterworth et al., 1979). Furthermore, 
in experiments using polyclonal anti-serum raised against eosinophils, immunity 
to helminths was found to be abolished (Mahmoud et al., 1975; Gleich et al., 
1993). Eosinophils have been linked with several diseases, particularly 
inflammatory skin diseases associated with oedema and certain endomyocardial 
diseases (Gleich et al., 1993). However, the commonest causes of raised blood 
eosinophil counts in Western countries are asthma and hayfever (Spry, 1988).
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1.4 The role of the eosinophil in asthma
Asthma is a condition often associated with atopy, particularly in children. Atopy 
occurs as a result of inappropriate synthesis of IgE, specific for particular 
external antigens (e.g. grass pollens). Atopic asthmatics who experience acute 
attacks upon exposure to the allergen to which they are sensitised, are termed 
'extrinsic' asthmatics. 'Intrinsic' asthma refers to patients who are not atopic and 
where IgE-dependent mechanisms do not appear to operate. A third clinical 
category known as 'occupational' asthma refers to patients who become 
sensitised after exposure to particular proteins, or small molecular weight 
compounds (Corrigan and Kay, 1992).
A role for the eosinophil in bronchial asthma was originally observed in 1889, 
when peripheral blood eosinophilia was found to be associated with asthma, 
whilst airway eosinophilia linked with asthma was first described in 1922 (Gleich 
et al, 1993). However, the emphasis for the role of eosinophils in asthma has 
changed over the last 20 years. This change of emphasis coincided with the 
understanding that asthma does not simply reflect acute airway obstruction, due 
to mast cell-mediated constriction of the airway smooth muscle. It is now 
understood that asthma is a chronic inflammatory disease with intermittent acute 
attacks. These acute bronchospastic episodes are thus superimposed on 
chronically inflamed airways tissues (Ackerman, 1989).
By the late 1970s, it was becoming clear that far from having a protective role in 
asthma, eosinophils were likely to have a pro-inflammatory effect in this disease. 
There was evidence for the presence of histaminase, an enzyme capable of
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degrading mast cell-derived histamine, in eosinophils. However, greater 
amounts of this enzyme were to be found in neutrophils than in eosinophils. In 
addition, it was found that eosinophils produce large amounts of the 
inflammatory mediators PAF and leukotriene C4 (LTC4) (Spry, 1988) Clinically, 
increased numbers of eosinophils have been found in the peripheral blood, 
sputum and bronchial tissue of asthmatic patients (Horn and Karnovsky, 1986; 
Baigelman et a/., 1983; de Monchy et ai, 1985). Furthermore, a correlation 
between eosinophil counts and clinical severity of asthma has been widely 
documented (Taylor and Luksza, 1987; Bousquet et al. 1990; Janson and 
Herala, 1992).
Marked changes occur in the physiology of the airways of chronic asthmatic 
patients. The airways become hyperresponsive and this correlates with the 
degree of inflammation and eosinophilia present. The inflammation causes 
hyperresponsiveness as a result of both an inflamed thickened airway wall, 
which encroaches on the lumen, as well as release of bronchoconstrictor 
inflammatory mediators (Reed, 1988). The bronchoconstrictor effect of these 
inflammatory mediators is enhanced by the loss of the epithelial layer. The 
epithelium forms a protective barrier in the airways and its loss exposes sensory 
neurones, which release neurotransmitters. Many of the inflammatory mediators 
amplify the bronchoconstrictor effects of neurotransmitters on the airway smooth 
muscle. Additionally, neurotransmitters (particularly neuropeptides) stimulate 
mast cell mediator release and dilate blood vessels (Reed, 1988).
Eosinophils are capable of producing many of the pathophysiological changes
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seen in asthma. Activation of eosinophils leads to the release of the potent 
cytotoxic pre-formed granule proteins and newly formed lipid mediators. These 
can cause submucosal oedema, enhancement of mucus secretion and non­
specific airway hyperreactivity (Gleich et ai, 1993). Detailed studies of the effect 
of MBP on the respiratory epithelium of guinea-pigs showed that it caused both 
detachment of epithelial cells, as well as impairment of ciliary beating (Frigas et 
a i, 1980). This leads to reduced clearance of mucus from the airways. 
Furthermore, high concentrations of MBP are present in the sputum of many 
asthmatics and elevated sputum MBP levels are used as a marker for bronchial 
asthma (Frigas et ai, 1981). Similarly, ECP is also cytotoxic to the respiratory 
epithelium and sputum ECP levels are elevated in asthmatics (Virchow et ai, 
1993).
EPO is also released from activated eosinophils and functions as a cationic toxin 
in the absence of hydrogen peroxide (H20 2) and as a peroxidase in the presence 
of H20 2 (Gleich et ai, 1993). EPO promotes the formation of hypohalous acid 
in the presence of H20 2 and halide ions (preferentially bromide) and may have 
an effect on acute changes in microvascular permeability (Yoshikawa et ai,
1993).
Eosinophil activation also leads to stimulation of a respiratory burst response, 
generating toxic oxygen radicals such as superoxide (0 2) and H20 2 (Dechatelat 
et a i, 1977). Reduced nicotinamide adenine dinucleotide (NADPH) oxidase, 
similar to that found in neutrophils, is also present in eosinophils (Bolscher et ai, 
1990). NADPH oxidase is an electron transport chain found in lymphocytes and
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in the wall of the endocytic vacuole of phagocytic cells. NADPH acts as an 
electron donor to reduce oxygen to 0 2 and H20 2 (Segal and Abo, 1993). In 
unstimulated cells, the enzyme consists of at least 3 cytosolic components (Rac, 
p47p/70X and p67p/,ox) and 3 plasma membrane subunits (cytochrome b558 
(comprising gp91p/,ox and p22phox subunits) and p45p/70X). Upon cell stimulation the 
cytosolic components are rapidly transferred to the plasma membrane, so that 
the enzyme is assembled and activated (figure 2) (Thelen e ta l, 1993).
Bronchoalveolar lavage (BAL) eosinophils were found to have a greater 
superoxide response than peripheral blood eosinophils (Sedgwick etal., 1992), 
suggesting that release of toxic oxygen radicals may also be involved in the 
asthmatic inflammatory response.
Eosinophils also produce many of the inflammatory mediators present in the 
airways of asthmatics. These include cyclo-oxygenase- and 5-lipoxygenase- 
derived arachidonic acid metabolites, namely prostaglandins (PGs) (PGE2l 
PGD2l PGF2q and thromboxane B2 (TXB2)) and leukotrienes (LTC4), respectively 
(figure 3) (Kroegel and Matthys, 1993; Bruynzeel etal., 1985). Leukotrienes are 
synthesised after liberation of arachidonic acid from arachidonyl-phospholipids 
within cell membranes or intracellular lipid bodies (Weller and Dvorak, 1985), 
probably via activation of a Ca2+-dependent, arachidonate-selective 
phospholipase A2 (Nigam et a i, 1995). Free arachidonic acid is converted to 
LTA4 by 5-lipoxygenase, in association with a membrane-bound 5-lipoxygenase 
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Activation of NADPH oxidase involves the formation of a complex of the cytosolic components 
of the enzyme (p47phox, p67phox and p21rac), which then associates with flavocytochrome B 
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Figure 3
Human eosinophils metabolise arachidonic acid via the 5-lipoxgenase pathway 
to yield LTC4) whilst metabolism via the cyclo-oxygenase pathway generates 
prostaglandins.
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with glutathione, by LTC4 synthase to form the sulphidopeptide LTC4. LTC4may 
be converted to LTD4 and LTE4 by the removal of L-glutamate and glycine 
residues. Collectively, leukotrienes C4, D4 and E4 constitute the agent formerly 
known as slow-reacting substance of anaphylaxis (SRS-A) (Samuelsson, 1983). 
In eosinophils, LTC4 is released from the cell via a specific, saturable export 
mechanism (Lam e ta l, 1989).
Human eosinophils have been shown to release LTC4 in vitro, in response to a 
range of stimuli, including fMLP, opsonised zymosan, PAF and the Ca2+ 
ionophore, A23187 (Takafuji et al., 1991). LTC4 may contribute to the 
inflammatory process in the lung by causing bronchoconstriction, changes in 
vascular permeability and tone, as well as increased mucus secretion (Spry,
1988). In addition, eosinophils have been shown to produce large amounts of 
PAF, which is a potent bronchoconstrictor agent as well as being an extremely 
effective chemotactic stimulus for eosinophils (Kay, 1991). It is clear that 
eosinophils play an important role in the pathogenesis of the airway inflammation 
associated with asthma. In order to exert their inflammatory effects, eosinophils 
are first selectively recruited to the site of inflammation.
1.5. Recruitment of eosinophils to an inflammatory site
Eosinophils develop from bone marrow precursor cells which divide and 
differentiate, acquiring their characteristic granules. This process is under the 
control of a number of growth factors or colony stimulating factors derived from 
T-lymphocytes and mesenchymal cells, particularly GM-CSF, IL-3 and IL-5. 
Following the process of differentiation and maturation, which takes
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approximately 5 days, the eosinophil leaves the bone marrow and enters the 
peripheral blood circulation (tV2~13-18 hours) before migrating into the tissue 
(Kroegel etal., 1994).
The process of eosinophil transmigration from the blood to the tissues at the site 
of an inflammatory reaction consists of several sequential steps. Normally there 
will be random contact of the eosinophils with the endothelium as they circulate 
in the peripheral blood, particularly in the smaller blood vessels (i.e. capillaries). 
However, the endothelial cells near an inflammatory site become activated by 
inflammatory mediators and rapidly express surface selectins. Selectins are cell 
adhesion proteins that bind to carbohydrate/sugar residues on their 
corresponding adhesion molecule ligands. Eosinophils express two saccharide 
adhesion molecules, namely CD15 and CDw65, which bind to the endothelial 
selectins CD62 and ELAM-1, respectively (Kroegel et al., 1994). The result of 
this initial reversible adhesion combined with the shear forces due to blood flow, 
leads to the leukocyte 'rolling' along the endothelial surface. The process of 
'rolling' is sufficient to slow the eosinophil's progress, allowing time for eosinophil 
activation by locally-released inflammatory mediators (Pilewski and Albelda, 
1993).
Eosinophils become activated as a result of the actions of locally released 
cytokines and inflammatory mediators, causing an increase in the number and 
affinity of eosinophil integrin adhesion molecules. The eosinophil pr integrin, 
VLA-4, binds to endothelial vascular cell adhesion molecule-1 (VCAM-1) 
receptors. Whereas the p2-integrin receptors leukocyte function associated
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antigen (LFA-1; CD11a/CD18), complement receptor 3 (CR3 or Mac-1; 
CD11b/CD18) and p150.95 (CD11c/CD18), bind to endothelial cell intercellular 
adhesion molecule-1 (ICAM-1) receptors. Integrin-mediated adhesion leads to 
a firmer adhesion or 'sticking' of eosinophils to the endothelium (Hansel and 
Walker, 1992)
Following firm adhesion to endothelial cells, eosinophils are stimulated by 
chemoattractants (e.g. IL-2, IL-5, RANTES and PAF) from the inflammatory area 
and migrate between the endothelial cells into the extracellular space 
('diapedesis'). In order to allow transmigration, the eosinophils shed surface L- 
selectin receptors thus weakening the adhesion of the eosinophils to the 
endothelium (Walker et al., 1993). The transmigrated cell moves along a 
chemotactic gradient, via increasing concentrations of chemotactic factors, as 
well as via the interaction of eosinophil integrins with matrix proteins, towards the 
inflammatory focus (Resnick and Weller, 1993). When the cell nears the 
inflammatory target, it is exposed to increasing concentrations of activating 
mediators and locally released cytokines, which activate the eosinophil causing 
it to release its cytotoxic granules and generate reactive oxygen species and 
inflammatory mediators (Kroegel et al., 1994). The process of selective 
recruitment and subsequent survival and activation of eosinophils in the tissues 
appears to be predominantly controlled by cytokines.
1.6 Role of cytokines on eosinophil recruitment, survival and activation.
The understanding of the processes which control the selective recruitment of 
eosinophils to an inflammatory site has increased dramatically during the past
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10 years. Identification of the adhesion molecule VLA-4, which is present on 
eosinophils, but not neutrophils, gave one possible mechanism for selective 
recruitment of eosinophils (Weller et al., 1991). It is now recognised that 
cytokine-mediated regulation of adhesion molecule expression also plays an 
important role in this process. IL-5, PAF and fMLP have been shown to cause 
upregulation of MAC-1 and down-regulation of L selectin on eosinophils. PAF 
and FMLP also had a similar effect on neutrophils, whereas the effect of IL-5 
was selective for eosinophils (Neeley et al., 1993). The predominant source of 
IL-5 in asthma is the T helper (Th) lymphocytes (CD4+). Recently, it has also 
been shown that eosinophils are themselves capable of synthesising IL-5 which 
may have autocrine and paracrine effects (Tanaka etal., 1994; Robinson et al., 
1993).
In addition to IL-5, IL-3 and GM-CSF also appear to play a major role in 
modulating the activity and survival of eosinophils in the tissues. The cell 
surface receptors for IL-3, IL-5 and GM-CSF have specific a chains, which bind 
to their corresponding ligand with low affinity. High affinity receptors are formed 
by the association of the a chain with a common p chain. This can lead to cross- 
inhibition between the cytokines when a limited number of p chains are present 
(Nicola and Metcalf, 1991). These cytokines have been shown to stimulate 
chemotaxis (Quan et al., 1993; Yamaguchi et al., 1988), as well as enhance 
eosinophil survival (Yamaguchi etal., 1991; Ohnishi etal., 1993; Rothenberg et 
al., 1988). Furthermore, it has been shown in vitro that blood eosinophils, from 
patients with allergic asthma, adhered to and transmigrated across a confluent 
layer of human umbilical vein endothelial cells, whereas eosinophils from normal
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donors did not transmigrate. Prior incubation of normal eosinophils with IL-3, IL- 
5 and GM-CSF caused the cells to adhere and transmigrate. Thus, it appears 
that blood eosinophils from allergic asthmatics have undergone in vivo priming 
and this can be mimicked in vitro by incubating the cells with certain cytokines 
(Moser et al., 1992). In vitro, bronchial epithelial cells (Soloperto et ai., 1991) 
and human lung fibroblasts (Vancheri et al., 1989) have been shown to produce 
GM-CSF and these cell types may be a source of GM-CSF in asthmatic airways.
IL-3, IL-5 and GM-CSF prime eosinophils to subsequent activating stimuli. The 
respiratory burst response is enhanced and this process appears to involve 
tyrosine kinase activity and is a Ca2+-independent process (van der Bruggen et 
al., 1993). Similarly, IL-3 and IL-5 have been shown to enhance release of LTC4 
from eosinophils stimulated with soluble stimuli, such as C5a, FMLP and PAF 
(Takafuji etal., 1991).
IL-5 has been detected in the serum and BAL fluid of asthmatics. In addition, 
increased numbers of IL-5 mRNA positive cells are present in the BAL and 
bronchial mucosa of asthmatic airways (Robinson et al., 1993). This provides 
further support for cytokines, particularly IL-5, playing a major role in asthma.
Recently, there has been interest in a novel class of small cytokines 
(chemokines) and their potential role in allergic inflammation. Chemokines 
comprise 2 subfamilies, which are classified by the first 2 cysteine groups in their 
primary structure. The cysteine groups are either separated by 1 amino acid 
(CXC, e.g. IL-8) or are adjacent (CC, e.g. RANTES, monocyte chemotactic 
peptide (MCP) and macrophage inflammatory protein (MIP)) (Baggiolini and
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Dahinden, 1994). Activation of eosinophils by RANTES and MIP-1a stimulates 
chemotactic responses (Rot et al., 1992; Kameyoshi et al., 1994), as well as 
generation of reactive oxygen species (Kapp etal., 1994). In contrast, RANTES 
and MIP-1a have no effect on neutrophils. RANTES also upregulates 
expression of MAC-1 (CD11b/CD18) (Alam etal., 1993), whilst the chemotactic 
responses are primed by IL-5 (Schweizer et al., 1994). Similarly, MCP-3 was 
recently found to be a potent chemotactic stimulus for human eosinophils (Noso 
et al., 1994; Dahinden et al., 1994), whereas MCP-1 has no effect. Most 
recently, interest has focused on the identification of a new chemokine eotaxin, 
which was initially extracted from the BAL of actively sensitised guinea-pigs after 
allergen challenge (Griffiths-Johnson etal., 1993). Both guinea-pig and human 
eotaxin have now been cloned (Jose etal., 1994a; Ponath etal., 1995). Eotaxin 
acts as a potent and specific chemoattractant in both guinea-pig and human 
eosinophils and appears to share a binding site with RANTES on guinea-pig 
eosinophils (Jose etal., 1994b).
1.7 Signal transduction pathways involved in eosinophil activation
Relatively few studies have investigated the signal transduction mechanisms in 
human eosinophils, following agonist-receptor interactions. This has mainly 
been due to technical difficulties in obtaining sufficient cells of high purity, from 
normal healthy donors. Until recently, density gradient techniques using either 
metrizamide or Percoll were used for the preparation of eosinophils. However, 
the overlap of the density of eosinophils and neutrophils meant that in order to 
obtain high purity of eosinophils, only low yields were achieved (Hansel et al.,
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1990). The advent of immunomagnetic cell separation has effectively overcome 
this problem. This technique does not rely on the density of the cells for 
separation, but utilises the fact that neutrophils, but not eosinophils, express the 
surface marker CD16. In a mixed granulocyte preparation, anti-CD16 
micromagnetic beads bind to neutrophils. When the cells are added to a 
magnetised column, neutrophils are retained whereas the eosinophils are eluted 
(Hansel et al., 1991). This technique permits both high yield and purity of 
eosinophils to be obtained, so that there are sufficient eosinophils from normal 
healthy donors to be able to investigate the biochemistry of these cells.
Agonist-induced stimulation of cells leads to activation of a complex cascade of 
intracellular messengers, which transduce the signal into a functional response. 
Classical signal transduction pathways, via heterotrimeric guanine nucleotide- 
binding proteins (G proteins), involve activation of adenylyl cyclase and 
phosphoinositide-specific phospholipase C (PLC) (Gilman, 1987; Berridge and 
Irvine, 1989). Activation of adenylyl cyclase stimulates the production of cyclic 
3',5-adenosine monophosphate (cAMP). The elevated levels of cAMP stimulate 
protein kinase A (PKA), which influences the activity of the cell by 
phosphorylating target proteins (Taylor, 1990).
The other major classical signal transduction pathway involves activation of PLC, 
which catalyses hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
form inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). DAG 
stimulates the activation of protein kinase C (PKC), whilst IP3 binds to specific 
receptors present on the membrane of intracellular Ca2+ stores, stimulating the
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rapid release of Ca2+ from this site (Berridge and Irvine, 1989; Ferris et al.,
1989).
Phospholipases A2 and D are also involved in the signal transduction processes 
in many cells. Phospholipase A2 is present in cell membranes and lysosomes 
and acts as a lipolytic enzyme to hydrolyse glycerol phosphatide, yielding 
lysophosphatide and arachidonic acid (White et al., 1993). Phospholipase D 
(PLD) catalyses the hydrolysis of choline-containing phosphogycerides to form 
phosphatidic acid (PA) and choline. Conversion of PA by PA phosphohydrolase 
yields 1,2-diradyl-sn-glycerol (DG), which stimulates PKC (Mullmann et al., 
1990a). Interest in the role of PLD in activation of phagocytic cells has focused 
on the neutrophil. Cytokine priming in neutrophils activates tyrosine kinase, 
which leads to enhanced coupling between membrane receptors and PLD 
(Bourgoin et al., 1992). Furthermore, PA appears to directly activate the 
neutrophil NADPH oxidase enzyme (Rossi etal., 1990).
Agonist-induced activation of the respiratory burst response in eosinophils, 
mediated via activation of NADPH oxidase, is inhibited by elevation of cAMP 
(Dent et al., 1994a; Barnette et al., 1995). Eosinophils appear to have a 
substantial capacity to generate 0 2, as stimulation of eosinophils with either the 
PKC activator, phorbol myristate acetate (PMA) or the calcium ionophore 
A23187, generates up to 3 times more 0 2, than the equivalent number of 
neutrophils (Petreccia et al., 1987; Cromwell et al., 1985). Bach et al (1992) 
found that the signal transduction processes controlling respiratory burst 
responses appear to be dependent upon which agonist is used. PMA-induced
0 2 release is blocked by several PKC inhibitors, whereas the response to IgG 
(coupled to Sepharose beads) was not inhibited. Conversely, wortmannin is 
extremely potent at inhibiting IgG- and PAF-mediated 0 2 release (IC50<0.7nM), 
but is much less active against PMA-induced effects (IC50=5pM). This suggested 
that at least 2 separate signal transduction pathways exist for 0'2 generation.
Recently, Wymann et al (1995) reported that while C5a-induced Ca2+ 
mobilisation and 0 2 release were inhibited by Ca2+ depletion, PMA-induced 
respiratory burst was not. In addition, the PMA response was more sensitive to 
inhibition by staurosporine, than C5a-mediated 0 2 generation.
In contrast to 0 2 generation, C5a- and PAF-induced EPO release are enhanced 
by staurosporine. PAF and C5a mediate their effects via Gr like G proteins, as 
pertussis toxin pretreatment abolishes the respiratory burst response, as well as 
exocytosis of EPO (Kernen et al., 1991).
PLD is also activated in human eosinophils by receptor (C5a) and non-receptor 
(PMA and A23187) agonists; suggesting that both PKC-dependent and - 
independent pathways for PLD activation are present in eosinophils (Minnicozzi 
etal., 1990).
Phospholipase A2, which catalyses the production of arachidonic acid, may also 
play a role in regulating eosinophil activation. Inhibition of PLA2 by mepacrine 
was found to inhibit fMLP-induced 0 '2, LTC4 and EPO release, whilst addition of 
exogenous arachidonic acid reversed this effect (White et al., 1993).
Recently, there has been some interest in the role of phosphatidylinositol 3-
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kinase (PI 3-kinase) during activation of the neutrophil respiratory burst 
response. Activation of PI 3-kinase, via tyrosine kinase-linked growth factor 
receptors, for mitogenic signals has been well documented (Cantley et al.,
1991). A recent report by Vlahos et al. (1995) found that inhibition of PI 3-kinase 
blocked fMLP, but not PMA-induced NADPH oxidase activity in human 
neutrophils.
There is also evidence that Ca2+ ions play an important role in regulating cell 
activity in human eosinophils. A variety of stimuli have been shown to elevate 
cytosolic Ca2+ levels in human eosinophils (Raible etal., 1992). PAF and fMLP 
stimulate both release of Ca2+ from intracellular stores, as well as Ca2+ influx 
(Sedgwick etal., 1992; Zoratti etal., 1991). Kernen et al. (1991) demonstrated 
that the chemotactic peptide C5a is a potent Ca2+ mobilising stimulus and that 
the release of eosinophil peroxidase is a Ca2+-dependent process. C5a- and 
PAF-induced [Ca2+]j changes are inhibited by activation of PKC (using PMA) and 
by pertussis toxin (PTX) pretreatment (Kernen et al., 1991).
It is clear that different responses involve different signal transduction pathways 
and that more than one pathway may be used for a particular response in human 
eosinophils. Moreover, different agonists appear to be able to mediate the same 
response via different second messenger systems (e.g. PMA- and IgG-induced 
respiratory burst).
1.8 Role of Ca2+ in cellular activation
An important determinant of cellular activation is the concentration of cytosolic
i
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free Ca2+([Ca2+];). Ca2+ plays a pivotal role in the excitation-contraction coupling 
of smooth muscle cells (Bolton, 1979; Rodger, 1987), as well as in stimulus- 
response coupling in inflammatory cells (Lew, 1989). However, in eosinophils 
very few studies have investigated the role of Ca2+, and the relative contribution 
of release of Ca2+ from intracellular stores and Ca2+ influx.
The level of [Ca2+]s in most unstimulated cells is approximately 100nM; this is 
some 10,000 fold lower than the extracellular Ca2+ concentration (Lew, 1989). 
This difference in Ca2+ concentration is maintained by a combination of 
homeostatic mechanisms, involving Na+/Ca2+ exchange (Blaustein and Nelson, 
1982), Ca2+ efflux via an ATP-dependent Ca2+ pump in the plasma membrane 
(Rickard and Sheterline, 1985) and sequestration of Ca2+ into intracellular stores 
via Ca2+/Mg2+-ATPase on endoplasmic membranes (Thastrup, 1990).
The source of elevation of [Ca2+]j during cell activation may come from 
intracellular Ca2+ stores and/or influx of extracellular Ca2+ across the plasma 
membrane. Non-excitable cells, such as neutrophils, respond to agonist 
stimulation with a biphasic elevation in [Ca2+]j comprising release of Ca2+ from 
intracellular Ca2+ stores, followed by the influx of extracellular Ca2+ into the 
cytosol (Montero etal., 1991).
1.9 Types of intracellular Ca2+ store
Receptor stimulation leads to PLC-mediated generation of IP3, which in turn 
activates Ca2+ release channels located within the membrane of intracellular Ca2+ 
stores (Krause et al., 1989). The intracellular storage of Ca2+ in human
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neutrophils is believed to be in specialised organelles, termed calciosomes, 
which contain the Ca2+-binding protein calreticulin (Krause etal., 1990). Virtually 
all non-muscle cells appear to possess intracellular stores with an IP3-gated Ca2+ 
release channel (Berridge and Irvine, 1989; Burgess et al., 1984; Satoh et al., 
1990), with at least 4 different IP3 receptors sub-types so far identified (Berridge,
1993).
In addition to, or instead of IP3 receptor-mediated intracellular Ca2+ release, 
many cell types possess ryanodine receptors. These receptors are able to bind 
the plant alkaloid ryanodine and were first described in the sarcoplasmic 
reticulum of skeletal muscle (RYR1) and cardiac muscle (RYR2) (Sorrentino and 
Volpe, 1993). Recently, a third ryanodine receptor has aroused a certain 
amount of interest, as it appears to be widely expressed and may be involved in 
calcium-induced Ca2+ release (CICR). CICR is thought to provide the positive 
feedback mechanism required to allow Ca2+ waves to propagate within the cell 
without fading. This process has been shown to occur in cardiac myocytes, 
mouse oocytes and pancreatic acinar cells (Taylor, 1994). A metabolite of NAD, 
cADP ribose has recently been found to act on certain types of ryanodine 
receptors to cause mobilisation of intracellular Ca2+ stores and may represent an 
endogenous regulator of these channels. cADP ribose has been found in 
several cell types, including sea urchin eggs (where its formation is stimulated 
by cGMP-dependent protein kinase), pancreatic acinar and p cells, as well as 
dorsal root ganglion cells (Taylor, 1994).
1.10 Ca2+ influx pathways
41
Ca2+ influx pathways may be divided into 2 major groups, according to their 
mechanism of activation (figure 4): voltage operated Ca2+ channels (VOCs) and 
receptor-mediated Ca2+ entry (RMCE).
Excitable cells (e.g. nerves and smooth muscle cells) mediate Ca2+ influx across 
the plasma membrane, via VOCs, as a result of membrane depolarisation. 
VOCs can be divided into 4 major subtypes, based on their electrophysiological 
properties, namely L-, T-, N- and P-type Ca2+ channels (Meldolesi and Pozzan, 
1987). Clinically, VOC-blockers are useful therapeutic agents. Potent 
dihydropyridine inhibitors of L-type Ca2+ channels (e.g. nifedipine) have proved 
to be effective in treating cardiovascular disorders, such as hypertension. In 
addition to their activation by plasma membrane depolarisation, VOCs may be 
regulated by G proteins, protein kinases and potentially by other second 
messengers (Dolphin, 1990; Naccache etal., 1990).
In contrast to excitable cells, non-excitable cells appear to use RMCE pathways 
as an important and abundant mechanism for Ca2+ entry (Meldolesi etal., 1991). 
Guinea-pig eosinophils are reported to activate RMCE pathway(s) when 
stimulated by LTB4 or PAF, as the Ca2+ responses are inhibited by EGTA and 
Ni2+, but not by classical dihydropyridine VOC-blockers (Subramanian, 1992; 
Kroegel etal., 1989a).
Benham etal. (1989) suggested an operational definition of RMCE as "any influx 
of Ca2+, consequent on receptor occupation and not dependent on
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Schem atic representation of different types of C a2+ channel, classified by their different routes of activation : 
V O C S  (m em brane depolarisation), RO Cs (direct ligand interaction), SM O C s (generation of second messengers  
by effector enzym es (E )) and SO Cs (depletion of intracellular C a2+ stores, detected by a putative C a2+ sensor (S)). 
Adapted from Penner et al., 1993.
depolarisation, that generates a biologically significant, localised or general 
increase in [Ca2+]j". Currently, there are no potent and selective inhibitors of 
receptor-mediated Ca2+ influx available. The best available tools for the study 
of this influx pathway are inorganic cations (e.g. Ni2+, La3+ and Cd2+) and several 
imidazole compounds, although all of these agents are also reported to inhibit 
VOC-mediated Ca2+ influx. In this study, Ni2+ and the imidazoles, SK&F 96365 
and econazole were used to investigate RMCE in human eosinophils. The 
structures of the imidazole RMCE inhibitors SC38249, SK&F 96365 and 
econazole are shown below:
Ni2+ has been shown to inhibit RMCE pathways, when used at relatively high 
(mM) concentrations, in HL-60 cells (Demaurex et al., 1992). The first imidazole 
reported to inhibit RMCE in platelets, smooth muscle cells and PC12 cells was 
SC 38249, but it was also found to inhibit Ca2+ efflux (Ciardo and Meldolesi,
1990). Subsequently, SK&F 96365 (1-p-[3-(p-methoxyphenyl)-propyloxy]-p- 
methoxyphenethyl-1 H-imidazole hydrochloride), which blocked L-type VOCs in 
smooth muscle cells, as well as RMCE in a range of non-excitable cells was
OMe Cl
SC38249 SK&F 96365 Econazole
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identified (Merritt et al., 1990). Both SK&F 96365 and an imidazole analogue, 
econazole, have been reported to inhibit RMCE in non-excitable cells, such as 
platelets, neutrophils, and HL-60 cells (Merritt et al., 1990; Montero et a i, 1991; 
Alonso-Torre et al., 1993).
Activation of RMCE has been proposed to occur via several different 
mechanisms (Meldolesi and Pozzan, 1987; Meldolesi etal., 1991). Receptors 
may be directly coupled to the channel or linked via a G protein. This type of 
pathway is often termed receptor-operated Ca2+ (ROC) influx and requires 
receptor occupancy for activation (Fasolato et al., 1994).
Alternatively influx may occur as a consequence of receptor occupation leading 
to the generation of a second messenger (second messenger operated Ca2+ 
(SMOC) influx) (Meldolesi and Pozzan, 1987). The final type of RMCE pathway 
is activated as a result of emptying of intracellular Ca2+ stores and is termed 
'capacitative' Ca2+ influx (Putney, 1986; Putney, 1990) or store-operated Ca2+ 
(SOC) influx. The original model of capacitative Ca2+ entry proposed that refilling 
of intracellular Ca2+ stores during cell activation occured via a direct influx of 
extracellular Ca2+ into intracellular Ca2+ stores (Putney, 1986). Subsequent 
adaptation of this model suggested that extracellular Ca2+ enters into the cytosol 
of the cell, rather than directly into the Ca2+ storage organelles (Putney, 1990; 
Takemura et al., 1989). The discovery of highly selective inhibitors of the 
endoplasmic reticulum Ca2+-ATPase has contributed greatly to our 
understanding of the regulation of capacitative Ca2+ entry (Thastrup, 1990; 
Thastrup et al., 1989). Inhibition of the endoplasmic reticular Ca2+ pump, by
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agents such as thapsigargin and cyclopiazonic acid, causes emptying of 
intracellular stores without the generation of any known second messengers. 
The depletion of the intracellular Ca2+ stores stimulates a persistent elevation of 
[Ca2+]j which is dependent upon the presence of extracellular Ca2+ (Thastrup et 
al., 1990).
The first demonstration of a highly Ca2+-selective current which was activated by 
store depletion was found in mast cells, by Hoth and Penner (1992) and was 
termed lCRAC (Ca2+ release-activated Ca2+current). The principle characteristics 
of this current are that it is activated by any mechanism that depletes intracellular 
Ca2+ stores, it has high selectivity for Ca2+ over K+ or Na+(>1000 fold), a very low 
unitary conductance (<100 femtosiemens) and is voltage independent. This 
store depletion-activated Ca2+ influx pathway is present in many different cell 
types, including neutrophils (Montero etal., 1991; Demaurex etal., 1994), mast 
cells (Hoth and Penner, 1992), T cells (McDonald etal., 1993; Premack etal.,
1994), endothelial cells (Hallam etal., 1989) and oocytes (Snyder etal., 1988) 
and appears to be an important and abundant mechanism for the regulation of 
[Ca2+1 during cell activation.
1.11 Techniques for measuring [Ca2+]j
Detection of changes in [Ca2+]j in cell populations has generally been made 
using either Ca2+-sensitive fluorescent dyes or measurement of radiotracer Ca2+ 
fluxes.
The radioisotope 45Ca2+ has been widely used to study the transport and
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distribution of Ca2+ in both stimulated and unstimulated cells. This technique has 
been used successfully to detect receptor-mediated Ca2+ influx, yielding 
comparable results to those using fluorescent dyes. However, the usefulness 
of this technique is limited by the high rate of 45Ca2+ uptake seen in unstimulated 
cells (Schilling etal., 1989).
The advent of Ca2+-sensitive fluorescent dyes, such as quin-2 and fura-2, has 
allowed direct real-time measurement of changes in [Ca2+]j. The esterified form 
(acetoxymethyl ester) of the indicator, which is uncharged and hydrophobic, is 
able to readily cross cell membranes. Once inside the cell cytosol, endogenous 
esterases cleave the acetoxymethyl ester from the dye, releasing the free acid 
form. The free acid is unable to cross cell membranes and is therefore trapped 
inside the cell. Once extracellular dye has been removed, fluorescence signals 
from the cytosolic dye can be used to measure [Ca2+]j.
The original fluorescent Ca2+-indicator quin-2 was developed by Tsien (1980). 
It binds to Ca2+ (Kd=115nM) and undergoes a rapid 5-6 fold increase in 
fluorescent intensity. The subsequent improved dye, fura-2, also binds Ca2+ 
(Kd=224nM), but is 30 times more fluorescent than quin-2. Additionally, fura-2 
is less sensitive to Mg2+ and less susceptible to photobleaching than quin-2. 
Furthermore, fura-2 exhibits a shift in excitation maximum, to a lower wavelength 
on Ca2+ binding, with little shift in the emission maximum. This has the 
advantage of allowing fura-2 to be used as a dual excitation indicator, with Ca2+- 
free fura-2 measured at 380nm and Ca2+-bound fura-2 measured at 340nm. The 
high level of quin-2 loading required in order to obtain a measurable
fluorescence signal causes problems with buffering of [Ca2+](. The improvement 
in the fluorescent properties of fura-2 has the advantage that lower levels of fura- 
2 are loaded into the cell and effectively overcomes this problem (Grynkiewicz 
etal., 1985). The only potential disadvantages associated with fura-2 relate to 
incomplete hydrolysis of the acetoxymethyl ester and its tendency to become 
compartmentalised in subcellular organelles (Thomas and Delaville, 1991).
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AIMS AND OBJECTIVES
The aim of this study was to investigate the role of Ca2+ during agonist-induced 
activation of human eosinophils. A pharmacological approach was used to 
characterise the type of Ca2+ influx and signal transduction pathways used during 
C5a-, fMLP-, thapsigargin- and LTD4-induced eosinophil activation. 
Measurement of activation was made by assaying for O2 , LTC4 and ECP 
release, which represent respiratory burst, 5-LOX-mediated metabolism of 
arachidonic acid and degranulation responses, respectively. A comparison was 
made of the effect of agents which modulate [Ca2+]j, with the effects observed on 
the different functional responses.
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2. MATERIALS AND METHODS
2.1 Purification of human eosinophils.
Human eosinophils were prepared essentially as previously described by Hansel 
etal. (1991). Human venous blood (50-100ml), from normal healthy donors, was 
taken into anti-coagulant (3.2% w/v trisodium citrate), diluted with an equal 
volume of Hepes-buffered, Hanks' balanced salts solution (HBSS), without Ca2+ 
or Mg2+ and overlaid on an isotonic Percoll solution (1.082 g/ml). After 
centrifugation (1000g, 20 min, 20°C), the supernatant and mononuclear cells at 
the Percoll interface were removed and discarded. The remaining granulocytes 
and erythrocytes were transferred to fresh tubes, to avoid contamination with 
mononuclear cells adhered to the sides of the tubes. Erythrocyte removal was 
carried out by either ammonium chloride or hypotonic lysis methods. The first 
method involved mixing the cells with ice-cold ammonium chloride lysis buffer 
(Hartnell et a i, 1990) and placing them on ice for 15 minutes. Hypotonic lysis 
required the cells to be mixed with 20ml of ice-cold double-deionised tissue 
culture water for 30 seconds, followed by addition of 20ml of 2x concentration 
HBSS; this process was repeated 3-4 times until all the red blood cells had been 
removed. After erythrocyte lysis, granulocytes were washed in RPMI 1640 
medium, containing 5mM EDTA and 2% foetal calf serum (RPMI-FCS). The 
supernatant was removed and the cell pellet was resuspended with anti-CD16- 
conjugated micromagnetic beads (Miltenyi Biotec GmbH; 10//I beads per 2.5 x 
107 granulocytes) diluted 1:4 in RPMI-FCS. The cells were incubated for 40 
minutes at 4°C, with occasional gentle mixing and then loaded onto a magnetic
column (Becton-Dickinson) containing RPMI-FCS. Immunomagnetically labelled 
neutrophils were retained in the column, whereas the eosinophils were eluted at 
a flow rate of 1-1.5 ml per minute. The purified eosinophils were washed and 
resuspended in HBSS without Ca2+ or Mg2+. Differential cell counts were 
performed, using Kimura stain (Kimura et ai, 1973), on whole blood, the 
granulocyte mixture after erythrocyte lysis and the purified eosinophil fraction. 
High yield (>95%) and purity (95% eosinophils) were obtained using this 
technique.
2.2 IP3 assay.
Human eosinophils used for measuring IP3 generation were prepared either from 
human venous blood from normal healthy donors, or from buffy coat 
preparations supplied by the Blood Transfusion Service. It was necessary to use 
the buffy coat preparations because of the very high number of cells required for 
this assay. However, comparable results were obtained using cells from either 
of these sources.
Purified human eosinophils (2-3 x 106 cells in a total reaction volume of 100//I) 
were resuspended in HBSS with Ca2+ and Mg2+ and pre-warmed at 37°C for 5 
minutes Antagonist/vehicle was added 5 minutes prior to the addition of 
agonist/vehicle and the reaction was stopped by the addition of 20^1 of ice-cold 
20% perchloric acid. The cells were kept on ice for 20 minutes, then centrifuged 
(2000g, 15 minutes, 4°C) and the supernatants transferred to fresh tubes. It was 
necessary to use acidic conditions when extracting IP3 from cells, to stop the 
association of IP3 with proteins. The supernatants were neutralised by adding
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1.5M KOH containing 60mM HEPES buffer and universal indicator, essentially 
as described by Palmer et a/. (1986).
Measurement of IP3 levels was made using the Amesham D-myo-lnositol 1,4,5- 
trisphosphate [3H] assay system (TRK 1000). This assay involves competition 
between unlabelled IP3 and a fixed amount of 3H-IP3 for binding sites on a 
bovine adrenal binding protein preparation. The tubes contained 100/4 of each 
of the following : assay buffer (0.1M tris buffer, pH 9.0, with 4mM EDTA and 
4mg/ml BSA), sample or IP3 standard (0.19-25 pmole per tube), 3H-IP3 and 
binding protein. The tubes were vortex mixed, incubated for 15 minutes on ice, 
then centrifuged (2000g, 15 minutes, 4°C). The supernatants were removed 
and discarded and the tubes carefully wiped with cotton buds to remove any 
adhering droplets of liquid. The pellets were resuspended in 1ml of 0.15M 
NaOH, incubated at room temperature for 10 minutes and 10ml of Optiphase 
scintillant added to each sample in scintillation vials. Counts were measured 
using an LKB (B-scintillation counter and IP3 levels were calculated from standard 
curve readings using GraphPad software.
2.3 Measurement of intracellular Ca2+ concentration ([Ca2*],).
Human eosinophils (2 x 106 cells/ml) were loaded with the fluorescent Ca2+- 
indicating dye, fura-2 acetoxymethyl ester (fura-2/AM) (0.5pM, 30 minutes, 
20°C). Fura-2/AM is a cell permeant dye which becomes trapped inside cells 
due to esterase cleavage of the acetoxymethyl ester groups, resulting in the 
generation of membrane impermeant fura-2 acid. The cells were washed twice 
and resuspended (106 cells/ml) in Hepes-buffered Tyrodes (HBT) solution,
52
containing 0.1% BSA. Fluorescence measurements were made using a 
spectrofluorimeter (Biomedical Instruments Group, Univ. of PA or LS50, Perkin 
Elmer fluorimeter) using excitation wavelengths of 340nm and 380nm, an 
emission wavelength of 510nm and a slit width of 10nm. [Ca2+]j was calculated 
from the ratio of fluorescence, using the equation described by Grynkiewicz et 
al. (1985):
(  R  -^ m in  )  S f2
[Ca2+] = Kd x
(  Rmax " R  )  ^ b 2
The Kd for fura-2 is 224nM, Rmax and Rmin represent the fluorescence ratio values 
at saturating and Ca2+-free conditions, respectively and S^/S^ represents to 
fluorescence ratio of Ca2+-free/ Ca2+-bound fura-2 at 380nm. Rmax was obtained 
by lysing the cells, using digitonin in the presence of 1mM CaCI2 and Rmin was 
acheived by subsequent addition of 10mM EGTA solution containing 0.1 mM 
KOH. KOH was present in the EGTA solution because elevation of the final 
pH>8 increases the affinity of EGTA for Ca2+ (Thomas and Delaville, 1991).
2.4 Mn2+ influx assay.
Mn2+ influx studies were carried out using the isosbestic (Ca2+ insensitive) 
excitation wavelength of 360 nm, an emission wavelength of 510nm and a slit 
width of 10nm. Mn2+ has a 50 fold higher affinity for fura-2 than Ca2+ 
(Grynkiewicz et al., 1985) and once bound quenches its fluorescence. The rate 
of Mn2+ influx was calculated as follows :
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AMn2+ = F0 - F40 + Fe
F0 = fluorescent intensity 0 seconds after Mn2+ addition.
F40 = fluorescent intensity 40 seconds after Mn2+ addition.
Fe = Mn2+ quench of extracellular fura-2.
This represents the degree of quench of fura-2 fluorescence that occurred over 
a period of 40 seconds (essentially as previously described by Demaurex et al. 
(1994)), as the rate of quench is relatively linear during this time. Corrections for 
Mn2+ quench of leaked fura-2, were made by adding the membrane impermeant 
heavy metal chelator DTPA (2mM) at the end of each run. Any increase in 
fluorescence represented 'unquenching' of extracellular dye and this was 
subtracted from the agonist-induced quench effects (figure 5).
2.5 Measurement of superoxide production.
Superoxide (0 2) production was assayed by measuring the superoxide 
dismutase-inhibitable reduction of ferricytochrome C, via absorbance readings 
made at 550nm (Pick and Mizel, 1981), using a THERMOmax microtitre plate 
(MTP) reader (Molecular Devices, Palo Alto, CA). Each well contained 
eosinophils (2.5 x 105 cells/ml), cytochrome C (110pM), HBSS with Ca2+ (1.3mM) 
and cytochalasin B (5.5pM), in a total reaction volume of 250pl. Kinetic readings 
of 0 2 production were measured at 37°C, over a 30 minute period at 9 second 
intervals, with plate agitation between readings. The first 10 minutes of the 
reaction were used to calculate 0 2' generation as the rate of release was 
relatively linear during this time. 0 2' release was expressed as nmol of 
cytochrome C reduced/2.5 x 105 cells/10 minutes and was converted
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Figure 5
Example trace of agonist-induced Mn2+ influx. Agonist (e.g. C5a) was added 60 
seconds prior to the addition of MnCI2  (1 mM). lonomycin (3pM) was added 60 
seconds after MnCI2f to give maximal quench of fura-2 fluorescence. 
Subsequent addition of DTPA (2mM) caused a small increase in fura-2 
fluorescence due to 'unquenching' of extracellular fura-2. Calculation of the rate 
of Mn2+ influx was calculated by measuring the extent of Mn2+ quench of fura-2 
in 40 seconds (F0  - F40), with quench due to extracellular dye subtracted (AFe).
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from absorbance values using the following equation :
AA = ECL
AA = change in absorbance (OD).
E= extinction coefficient for reduced cytochrome C at 550nm (21 x 103  cm' 1 
(Massey, 1959)).
C = concentration of cytochrome C (cyt C) reduced (moles/litre).
L=light path (0.78cm)
AA = (21x103) x mol/litre x 0.78 
AA = (21x103) x nmoles/nlitres x 0.78 
nmoles = (AA x nlitres)/(21x103  x 0.78)
Volume = 250/J (= 2.5x105  nl) 
nmoles = (AA x 2.5x105 )/(21x103  x 0.78) 
nmoles cyt C reduced = AA x 15.26 
AA measured as mOD per minute
nmoles cyt C reduced per minute = AA x 15.26 x 10' 3  
Values were adjusted to represent 1ml reaction volume (=2.5x105  cells) and 10 
minute duration:
nmoles cyt C reduced/10 mins/2.5x105  cells = AA x 15.26 x 10' 3  x 10 x 4 
nmoles cyt C reduced/10 minutes/2.5x105 cells = 0.61 x mOD/min
Immediately after the assay the plates were centrifuged, the supernatants 
removed and transferred to fresh plates, covered with cling film and frozen
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(-20°C) until it was convenient for an LTC4  assay to be performed on the cell 
supernatants.
2.6 Measurement of LTC4  release.
Previously frozen MTPs were removed from the freezer and allowed to thaw at 
room temperature. The cell supernatants were then assayed for the presence 
of LTC4  by radioimmunoassay, essentially as described in the Amersham kit 
(TRK 910). The assay involves competition between ‘cold’ LTC4and a fixed 
amount of 3 H-LTC4  for a limited amount of rabbit anti-human LTC4  antibody. 
The antibody used also cross-reacts with LTD4  (100%) and LTE4  (30%). The cell 
supernatants or LTC4  standards (12.5 - 800pg LTC4  per tube) were mixed with 
equal amounts of 3 H-LTC4  and a rabbit anti-human LTC4  antibody and incubated 
for 1 hour, at 37°C in a shaking water bath. In early experiments the bound and 
unbound 3 H-LTC4were separated by addition of an activated-charcoal/dextran 
mixture and kept on ice for 10 minutes, followed by centrifugation ( 2000g, 15 
minutes, 4°C). The supernatants were decanted into scintillation vials, 10 ml 
optiphase scintillant added and counts were performed on an LKB p scintillation 
counter. In later experiments the assay was simplified by the availability of 
Scintillation Proximity Assay (SPA) reagents which removed the necessity to 
separate bound and unbound 3 H-LTC4, as well as the need to add scintillant, this 
enabled the assay to be performed in 96 well plates. SPA reagent contains 
fluomicrospheres bound to a second antibody. Any radiolabelled-ligand bound 
to primary antibody will bind to the secondary antibody on the fluomicrospheres 
and will cause emission of light. Generic anti-rabbit IgG SPA beads were added
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to the supernatant/3 H-LTC4 /anti-human LTC4  antibody mixture, the plates were 
then shaken overnight on an orbital shaker and counts were performed using a 
Packard topcounter. LTC4  levels were calculated from standard curve readings 
using GraphPad or Prism software. The %B/B0  standard curves obtained using 
either RIA or SPA techniques were the same (figure 6 A).
2.7 Measurement of Eosinophi! Cationic Protein (ECP) release.
Eosinophils were incubated in a plate shaker for 5 minutes at 37°C in a 96 well 
MTP, prior to the addition of antagonist/vehicle. Each well contained eosinophils 
(1.2 x 105  cells/ml), HBSS with Ca2+ (1.3mM) and cytochalasin B (5.5pM), in a 
total reaction volume of 250pl. The plate was incubated for a further 5 minutes 
prior to the addition of agonist/vehicle and the cells returned to the incubated 
plate shaker for 30 minutes. The MTP was centrifuged (350g, 5 mins, 4°C) and 
the supernatants transferred to a fresh MTP and frozen at -20°C, until it was 
convenient to perform the ECP radioimmunoassay. Frozen supernatants were 
thawed at room temperature and ECP levels were measured using a Pharmacia 
kit. Cell supernatants were mixed with equal amounts of 1 2 5 I-ECP and rabbit 
anti-human ECP antibody and shaken for 3 hours at room temperature. At this 
stage the method was altered from that described in the kit. Anti-rabbit SPA 
beads were added instead of the supplied decanting suspension of sepharose 
anti-rabbit IgG, which requires separation of bound and unbound 1 2 5 I-ECP and 
addition of scintillant. The plate was shaken overnight on an orbital shaker, then 
counted on a Packard Topcounter. ECP values were calculated from a standard 
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Figure 6
(A) Comparison of standard curves to LTC 4  and (B) ECP, when measured either 
by RIA or SPA  techniques. Data represent m ean ± standard deviation of 
duplicate standard solutions.
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RIA (using the example values given in the kit instructions) or SPA techniques 
were the same (figure 6 B).
2.8 Analysis of Data.
Results are expressed as either mean ± standard error of the mean (s.e.m) or 
mean ± 95% confidence intervals. Mean EC5 0  or IC5 0  values were calculated by 
linear regression analysis. Statistical significance was determined using 
Students' paired t-test on raw data, with p<0.05 taken as significant. Throughout 
this thesis ‘ denotes p<0.05 and " denotes p<0.005. P values reported are for 
comparisons of individual groups with control group. Since multiple comparisons 
were made with a single control group, type I error rates are likely to exceed 
those reported.
2.9 Materials.
Materials were obtained from the following sources:
Affiniti (formerly Biomol; Exeter, U K ): R59022, rolipram, U73122 and U73343.
Bayer : SK&F 96365 was synthesised 'in house' by Dr S Tudhope (Bayer PLC, 
Stoke Court, UK). BAY x1005 and WEB 2086 were supplied by the Chemistry 
department, (Bayer AG, Wuppertal, Germany) and cyclosporin A was supplied 
by Bayer Inc. (Westhaven, USA).
BDH Lab Supplies (Poole, UK) : CaCI2, MgCI2, MnCI2, NiCI2, KCI, NaCI and 
Na2 HPQ4.
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Calbiochem (Nottingham,UK) : bisindolymaleimide (GF109203X; 3-[1-(3- 
dimethylaminopropy!)-indol-3-yl]-3-(indol-3-yl)-maleimide), calyculin A, erbstatin 
analogue (methyl 2,5 dihydroxcinnamate), fura-2/AM, manoalide, SK&F 525A 
and wortmannin.
Eurogenetics (Middlesex, U K ): CD16 microbeads.
GIBCO (Life Technologies; Paisley, Scotland, UK) : RPMI 1640 medium (L- 
glutamine free).
ICN Flow (Thame, U K ): foetal calf serum (FCS).
Molecular Probes (Oregon, U S A ): benzamil
Porton Products (Maidenhead, U K ): pertussis toxin
R & D Systems (Abingdon, U K ): anti-CD11b and anti CD18
Sera-Lab (Crawley Down, U K ): HBSS (without phenol red) and HBSS (without 
phenol red, Ca2+ or Mg2+).
Sigma (Poole, U K ): A23187, low endotoxin (<0.1ng/mg) bovine serum albumin 
(BSA), human recombinant complement fragment 5a (C5a), cromakalim, 
cytochalasin B, diltiazem, diethylenetriaminepentaacetic acid (DTPA), 
econazole, ethylenediaminetetaacetic acid (EDTA), ethylene glycol-bis(p- 
aminoether) N,N,N,N'-tetraacetic acid (EGTA), ferricytochrome C, fMLP, 
forskolin, HBSS (10x) with phenol red, HBSS (10x) without phenol red, Hepes, 
indomethacin, isoprenaline, leukotriene D4  (LTD4), nifedipine, okadaic acid,
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Percoll, phorbol myristate acetate (PMA), salbutamol, sodium cromoglycate, 




Unless otherwise stated, drug solutions were dissolved in either double 
deionised tissue culture water or dimethyl sulphoxide (DMSO) and were diluted 
as appropriate. The final concentration of DMSO present in the cell suspensions 
was * 0.3%.
C5a was dissolved in phosphate buffered saline (PBS) containing 0.1% BSA and 
was immediately aliquoted and frozen (-20°C). Aliquots were removed from the 
freezer just prior to an experiment and kept on ice.
Fura-2/AM (10‘3 M) was dissolved in DMSO and immediately aliquoted and 
frozen (-20°C). Solutions were stored in the dark and tubes were covered with 
aluminium foil when cells were loaded with fura-2/AM in order to prevent 
photobleaching.
The composition of Hepes-buffered tyrodes (HBT) solution was as follows : 
NaCI (11.5mM), KCI (5mM), MgCI2  (1mM), Na2 HP0 4  (0.5mM) and Hepes 
(10mM), glucose (5.5mM) and 0.1% BSA.
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3. RESULTS
3. ACTIVATION OF HUMAN EOSINOPHILS
3.1 Spontaneous eosinophil activation
Initial attempts to measure agonist-induced 0~2 release were hampered by the 
ability of eosinophils, in the absence of exogenous agonist, to produce 
substantial quantities of O2  equivalent to 5.0 ± 0.4 nmoles cytochrome C 
reduced/ 10 mins/ 2.5x105 eosinophils (n=20). Under these conditions, no 
further 0~2 release was detected upon addition of C5a or FMLP (data not shown). 
Therefore it was necessary to determine the source of this spontaneous 
activation and how it could be removed, in order to allow measurement of 
agonist-induced eosinophil Oj release. Since it had previously been shown by 
Dri et al. (1991) that 0~2 release could be stimulated by eosinophil contact with 
ELISA plate plastic, the possibility that the spontanous activity seen in this study 
was due to contact of eosinophils with the MTP plastic was investigated. Pre­
treating the MTP with the matrix protein laminin (3pg/ml, 2 hours, 37°C) markedly 
inhibited (69.7 ± 6.3 %) Oj release.
It was also clear from the work of Sedgwick et al. (1993) that it was possible to 
measure Oj release using MTPs without any spontaneous activity. The major 
difference between their assay conditions and those being used in this study 
being the presence of gelatin (0.1%) in their buffer. Addition of gelatin (0.05%) 
to the HBSS did indeed inhibit the spontanous activity (96.1 ±1 .3  %).
Finally, addition of 5.5pM cytochalasin B, which blocks polymerisation of
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monomeric actin and thus blocks adhesion of the cells to the plastic, abolished 
spontaneous 0~2 release (figure 7 A). Cell morphology studies confirmed that 
cytochalasin B did inhibit the adherence of eosinophils to the surface of the MTP 
plastic (figure 8 ). However, this adhesion process did not appear to involve 
MAC-1 or any of the p2 integrins, as anti CD18 and anti CD11b antibodies had 
no effect on the spontaneous O2  response (figure 7B).
There did appear to be some very variable spontaneous LTC4  release (240.8 ±
128.4 pg LTC4 /2 .5x10s cells/30 mins, n=5) and addition of cytochalasin B did 
appear to reduce this (31.2 ± 28.0 pg LTC4  / 2.5x10s cells / 30 mins, n=5), 
although it did not acheive statistical significance. Similarly, a basal level of 
spontaneous ECP release (27.1 ± 6.2 ng ECP /1.2x104  cells / 30 mins, n=4) was 
detected, however this was not inhibited (7.5 ± 21.3 %) by cytochalasin B 
(5.5pM). Subsequent studies investigating agonist-induced eosinophil activation 
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Figure 7
(A) Effect of pre-treatment of the microtitre plate (M TP) with laminin (3pg/ml, 2 
hours, 37°C), or addition of gelatin (0 .05% ) or cytochalasin B (5.5pM ) to the 
assay buffer (n=4-5 separate experiments) and (B) effect of anti CD18, anti 
C D 11b (n=5) or a combination of anti C D 18/C D 11b  (n=2) antibodies on 
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Figure 8
A ppearance of human eosinophils on the surface of a microtitre plate in the 
presence and absence of cytochalasin B (Original Magnification x900).
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3.2 C5a-induced human eosinophil activation : effects on IP3 generation, 
[Ca2 +]j, Mn2+ influx, O 2 , LTC4and ECP release.
C5a (0.03-30 nM) caused concentration-dependent increases in [Ca2+]iP (figure 
9A) and rate of Mn2+ influx. [Ca2 +]j, was elevated from a basal level of 74.9 ±
14.7 nM to a maximum of 538.5 ± 49.2 nM (n=4) by C5a (30nM). 0'2i LTC4  and 
ECP were released in response to C5a, being maximally stimulated at a 
concentration of 30 nM (figure 9B). The levels of 0~2, LTC4  and ECP released by 
C5a (30nM) were 11.6 ± 0.7 nmoles cytochrome C reduced/2.5x105  cells/10 
mins, 985.5 ± 146.5 pg LTC4 /2.5x105 cells/30 mins and 121.9 ± 10.5 ng 
ECP/1.2x104  cells/30 mins, respectively. These levels of CX,, LTC4  and ECP 
release are within the same range as the values obtained for the control groups 
reported in section 4. Mean EC5 0  values for C5a-induced eosinophil activation 
are shown below (table 1 ).
Table 1. Mean ECS 0  values for C5a-induced eosinophil activation
C5a-induced 
eosinophil activation
Mean ECS 0 (nM) 95% confidence limits
IP3  release 16.2 3.9 - 6 6 . 6
A[Ca2l 0.4 0 .0 2 - 6 . 2
Mn2+ influx 0 . 1 0.02 - 0.5
Oj release 0.9 0 .7 - 1 . 2
LTC4  release 1.5 0 .8 - 2 . 8
ECP release 2 . 6 1.3-5.1
Data represent mean of 4-7 separate experiments
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Figure 9
(A) Effect of increasing concentrations of C5a on C a2+ mobilisation in fura-2* 
loaded human eosinophils and (B) comparison of concentration-effect curves for 
peak increase in [Ca 2 +]j, Mn2+ influx, 0 '2, LTC 4  and ECP release. Data represent 
m ean ± s.e.m. of at least 4 separate experiments.
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than O ,^ LTC4  and ECP release, suggesting that other signal transduction 
pathways are activated in addition to Ca2+ mobilisation.
IP3  generation was also detected upon addition of C5a (30nM), with the peak 
increase detected when the reaction was stopped 5 seconds after agonist 
addition (figure 10A). All subsequent IP3  measurements were made using this 
5 second protocol. Comparison of the concentration-effect curves to C5a- 
induced IP3  generation and increases in [Ca2+]j (figure 10B) showed a large 
discrepancy in potency, with IP3  release not detected until a concentration of 
30nM C5a was added. However, this may purely be due to the fact that the 5 
second time point was selected from data obtained using 30nM C5a and lower 
concentrations of C5a may require a different period of time to acheive their 
maximal IP3  generation.
3.3 Thapsigargin-induced human eosinophil activation : effects on 
[Ca2+]j, O i, LTC4 and ECP release.
Thapsigargin (1nM-1pM), a selective endomembrane Ca2 +/Mg2+-ATPase 
inhibitor, stimulated a concentration dependent Ca2+ influx response in human 
eosinophils (figure 11). This demonstrates the existence of a store-regulated 
Ca2+ entry pathway in human eosinophils. Interestingly, there was a substantial 
difference in the level of elevation of [Ca2+1 depending on when Ca2+ was added 
to the cells. Addition of Ca2+ after thapsigargin stimulated a much larger 
increase in [Ca2+], than when thapsigargin was added to cells which were already 
in the presence of Ca2+ (figure 12A). When the concentration-effect curves were 
























(A ) Time-course of C5a (30nM )-induced IP 3 generation and (B) comparison of 
concentration-effect curves for C5a-m ediated elevation of [Ca2+]j and IP 3  
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(A) Comparison of the extent of elevation of [Ca2+]j stimulated by increasing 
concentrations of thapsigargin added either before or after the addition of 1.3mM  
C aC I2. Any [Ca2+]j rise seen with vehicle alone was subtracted from the 
thapsigargin-induced effects. (B) Comparison of concentration-effect curves to 
thapsigargin for elevation of [Ca2+]j with LTC 4  release. Data represent mean ±  
s.e.m . of 3 separate experiments.
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thapsigargin was unaffected by pre- or post-addition of Ca2+ (figure 12B). 
Thapsigargin did not stimulate any O2  or ECP release either in the presence or 
absence of cytochalasin B, but did cause substantial LTC4  release both in the 
presence (457.3 ± 121.0pg LTC4 /2.5x105  cells/30 mins) and absence (488.12 ±
175.2 pg LTC4 /2.5x105  cells/30 mins) of cytochalasin B. However, the potency 
of thapsigargin for stimulation of LTC4  release was lower than that for stimulating 
[Ca2+]j rises. The amount of LTC4  release is within the same range as the values 
obtained for the control groups reported in section 4. Mean EC5 0  values are 
shown in table 2 .
Table 2. Mean EC 5 0  values for thapsigargin-induced eosinophil activation
Thapsigargin-induced 
eosinophil activation
Mean EC5 0  (nM) 95% confidence limits
A[Ca2l  (with Ca2+) 1 2 . 1 4.9 -30 .1
A[Ca2+]j (Ca2+ readdition) 9.7 7 .6 -12 .3
LTC4  release (with Ca2+) 228.9 168.4-310.9
Data represent mean of 3-4 separate experiments
3.4 FMLP-induced human eosinophil activation : effects on [Ca2 +]j, O2 , 
LTC 4  and ECP release.
FMLP (1nM-1pM) caused concentration-dependent increases in [Ca2 +]j, (figure 
13A), from a basal level of 113.6 ± 11 . 8  nM to a maximum of 280.4 ± 28.0 nM 
(n=8 ). 0'2t LTC4and ECP were released in response to FMLP, being maximally 
stimulated at a concentration of 1pM (figure 13B). The levels of O ,^ LTC4  and 
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(A) Effect of increasing concentrations of FMLP on C a2+ mobilisation in fura-2  
loaded human eosinophils and (B) comparison of concentration-effect curves for 
peak increase in [Ca 2 +]j, O 2 , LTC 4  and ECP release. Data represent mean ± 
s.e.m . of at least 4 separate experiments.
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reduced/2.5x105  cells/10 mins, 1.08 ± 0.25 ng LTC4 /2.5x105  cells/30 mins and 
112.4 ± 12.5 ng ECP/1.2x104  cells/30 mins, respectively. These levels of O^ , 
LTC4  and ECP release are within the same range as the values obtained for the 
control groups reported in section 4. Mean EC5 0  values for FMLP-induced 
eosinophil activation are shown in table 3. A similarity between FMLP-induced 
eosinophil activation and C5a-mediated responses was that increases in [Ca2+]j 
occured at lower concentrations than 0~2, LTC4  and ECP release and may 
suggest that other signal transduction pathways require activation in addition to 
Ca2+ mobilisation.
Table 3. Mean EC5 0  values for fMLP-induced eosinophil activation
FMLP-induced 
eosinophil activation
Mean EC50 (nM) 95% confidence limits
A[Ca2l 1 1 . 1 4 .1 -3 0 .0
0~2 release 35.2 27.1 -45.8
LTC4  release 56.0 46.4 - 67.5
ECP release 35.6 5 .9 -216 .9
Data represent mean of 3-10 separate experiments
3.5 LTD4-induced human eosinophil activation : effects on [Ca2*],, Mn2+ 
influx, 0~2 and ECP release.
LTD4  (100nM) stimulated a rapid and transient peak elevation of [Ca2+]j (figure 
14A) from a basal level of 110.0 ± 6.5 nM to a peak value of 293.4 ± 20.2 (n=8 ), 
which desensitised to a repeated addition of LTD4i but did not cross-desensitise 
with subsequent LTB4  (100nM) addition (data not shown). In addition LTD4
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(100nM) stimulated Mn2+ influx in human eosinophils (figure 14B). However, 

















(A) Effect of LTD 4 (100nM ) on [Ca2+]| and (B) stimulation of M n2+ influx by LTD 4  
in fura-2 loaded human eosinophils. Traces are representative of 4  separate  
experiments.
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4. RESULTS: MODULATION OF HUMAN EOSINOPHIL ACTIVATION
4.1 Spontaneous eosinophil activation
4.1.1 Investigation of the role of Ca2+ in spontaneous 0'2 release
A range of agents which modulate Ca2+-dependent effects were tested against 
spontaneous 0~2 release. Chelation of extracellular Ca2+ by EGTA caused a 
concentration-dependent inhibition of the response, with a mean IC5 0  value of 1.1 
(0.6-1.9) mM. This suggested that the spontaneous 0~2 release was dependent 
on the presence of extracellular Ca2+. Investigation of the type of Ca2+ influx 
pathway that might be involved in the responses was carried out using agents 
which inhibit VOCs and RMCE; mean data are shown in figure 15A and below 
in table 4.
Table 4. Effect of agents that modulate Ca2+ influx, on spontaneous 0 2  release.
Inhibitor Concentration
(M)
% Inhibition of 
spontaneous Oj release 
Mean ± SEM
EGTA 3x1 O' 3 92.4 ± 4.0**
NiCI2 3x1 O' 3 85.5 ± 4.5**
SK&F 96365 1x1 O' 5 80.2 ±16.7*
Nifedipine 1 x 1 0 ‘ 6 7.3 ± 27.4
Diltiazem 1x1 O' 5 16.9 ±4 .3
KCI 5x10* 2 12.5 ±13
Benzamil 3x10 ‘ 5 98.2 ±1.8*
Data represent mean ± s.e.m. of 3-8 separate experiments, * denotes p<0.05, 
** denotes p<0.005.
Both NiCI2  and SK&F 96365 which block both RMCE and VOCs caused a
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concentration-dependent inhibition of spontaneous Oj release, with IC5 0  values 
of 0.8 (0.2-3.9) mM and 3.5 (1.6-7.5) pM, respectively. In contrast, the potent 
and selective L-type VOC-blockers nifedipine and diltiazem had no effect 
against this response. This suggests that the Oj release involved Ca2+ influx via 
a RMCE, rather than a VOC-mediated pathway. However, depolarisation of the 
cell membrane by addition of KCI had no effect on the response. Finally, the 
Na+/Ca2+-exchange inhibitor benzamil caused marked inhibition of spontaneous 
Oj release at a concentration of 30pM.
4.1.2 Investigation of the second messengers involved in spontaneous Oj 
release.
Investigation of the second messengers that might be involved in the responses 
was carried out using a range of agents which modulate second messenger 
activation; mean data are shown in table 5 and are represented graphically in 
figure 15B.
Sodium fluoride (NaF, 30mM), which causes general activation of heterotrimeric 
G proteins, caused marked inhibition of spontaneous Oj release. This suggests 
that inhibitory G protein(s) may be activated by NaF and may stimulate 
generation of inhibitory second messengers.
Activation of PLC appeared to be involved, as U73122 (1pM), an inhibitor of 
PLC-dependent processes (Smith et a/., 1990), abolished the response. 
Whereas, U73343, a close structural but inactive analogue of U73122 was 
without effect, indicating some selectivity of action. In contrast, the
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phospholipase A2 (PLA2) inhibitor manoalide had no effect.
Table 5. Effect of agents that modulate second messengers, on spontaneous 
0 2  release.
Inhibitor Concentration
(M)
% Inhibition of 
spontaneous 0 2  release 
Mean ± SEM
NaF 3x1 O' 2 84.7 ± 1.4”
U73122 1x1 O' 6 96.7 + 1.7**
U73343 1x1 O' 6 6 . 6  ± 1 0 . 6
Manoalide 1x1 O' 6 3.6 ±4.2
Wortmannin 1x1 O’ 8 83.7 ±13.1*
Forskolin 3x1 O’ 5 35.2 ±21.0
Nitroprusside 1x1 O’ 6 9.9 ±4 .7
Staurosporine 3x1 0*8 44.2 ± 29.4
Erbstatin analogue 3x1 O' 6 8 8 . 6  ± 6 .8 *
Calyculin A 1 x 1 0 ‘ 7 -28.9 ± 22.9
Okadaic acid 1x1 O’ 6 -2.3 ±13.3
Cyclosporin A 1 x 1 0 “® 75.4 ±15.2*
Data represent mean ± s.e.m. of 3-4 separate experiments, ‘ denotes p<0.05, 
** denotes p<0.005.
Wortmannin (10nM) caused marked inhibition of the spontaneous 0 2  release. 
At this concentration wortmannin acts as a relatively selective PI-3 kinase 
inhibitor (Arcaro and Wymann, 1993), whereas inhibitory effects seen at higher 
concentrations (1pM) are generally due other effects, such as inhibition of 
tyrosine kinase and/or PLD (Naccache etal., 1993).
Elevation of cGMP by sodium nitroprusside had no effect on the response, whilst 
elevation of cAMP byforskolin or inhibition of PKC by staurosporine caused 
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(A) Effect of agents which inhibit C a 2+-dependent effects and (B) modulate  
second messengers, on spontaneous O 2  release. Data represent mean ± sem  





There appears to be a role for tyrosine kinase in this response, as the erbstatin 
analogue caused concentration-dependent inhibition, with an IC5 0  value of 1.2 
(0.6-2.5) pM.
Investigation of the effect of phosphatase inhibitors found that the protein 
phosphatase 2B (PP2B) inhibitor cyclosporin A, caused marked inhibition of the 
spontaneous Oj response, whereas the PP1 and PP2A inhibitors okadaic acid 
and calyculin A were without effect.
4.1.3 Investigation of the effect of selected pharmacological reference 
agents on spontaneous Oj release
A range of pharmacological reference agents which possess anti-inflammatory 
activity or are used in asthma therapy, were tested for their effects against the 
spontaneous generation of Oj in human eosinophils; mean data are shown in 
table 6 .
Table 6 . Effect of anti-asthma/anti-inflammatory agents on spontaneous Oj 
release.
Inhibitor Concentration % Inhibition of
(M) spontaneous Oj release 
Mean ± SEM
Cetirizine 1x1 O' 5 6 . 8  ±6 .9
Cromakalim 1 x 1 0 ‘ 5 20.1 ±29.2
Sodium cromoglycate 1 x 1 0 -® 15.5 ±17.3
Salbutamol 1 x 1 0 -® 1 2 . 2  ± 8 . 2
Indomethacin 3x1 O'® 25.4 ± 27.0
BAY x1005 (n=2) 1x1 O' 5 5.1 ±16.8
Data represent mean ± s.e.m. of 3-4 separa te experiments, unless otherwis
stated.
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The 3 2-agonist salbutamol, the potassium (KATP) channel opener cromakalim, the 
histamine antagonist cetirizine, as well as sodium cromoglycate had no 
significant effect on the spontaneous release of 0 2. Also, release of 
prostaglandins or leukotrienes did not appear to contribute to the response as 
the cyclo-oxygenase (COX) inhibitor, indomethacin and the leukotriene synthesis 
inhibitor (LSI), Bay x1005 were without effect.
In summary, spontaneous 0 2  release appears to be dependent upon Ca2+ influx 
via a receptor-mediated entry pathway. In addition, the response is mediated via 
PLC activation, as well as PI-3 kinase, tyrosine kinase and PP2B activation.
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4.2 C5a-induced human eosinophil activation
4.2.1 Investigation of the role of Ca2+ in C5a-induced eosinophil activation
A range of agents which modulate Ca2+-dependent effects were tested against 
C5a-induced eosinophil activation; mean data are shown below in table 7 and 
are represented graphically in subsequent figures.
Table 7. Effect of agents that modulate Ca2+ influx, on C5a-induced increases 
in [Ca2 +]j, Mn2+ influx, CX,, LTC4  and ECP release.
Inhibitor Cone(M)











EGTA 3x1 O' 3 *34.7 ± 3.9" nt 95.6 ± 2.8** 95.1 ± 3.6“ 5.2 ±5.5
NiCI2 3x10 3 58.3 ± 6.5" 73.6 ± 2.2** 97.9 ± 0.9“ 79.5 ± 6.2“ 77.1 ± 2.3”
SK&F 96365 3x1 O' 5 -1.9 ±13.5 69.1 ± 6.7** 90.5 ± 5.5“ 89.7 ± 5.3” 39.4 ± 2.3”
Nifedipine 3x1 O'® *-1.8 ±14.5 #8.5 ± 12.9 24.4 ± 9.3* 28.8 ±16.3 5.8 ± 5.5
Diltiazem 1x1 O' 5 nt nt 1.7 ± 11.6 30.3 ±15.2 5.5 ±6.1
Verapamil 3x1 O'® nt nt 5.2 ± 7.8 37.7 ±12.1* *-4.7 ± 7.2
Econazole 3x10® nt nt 91.6 ±17.9” 76.7 ±18.1” nt
KCI 5x1 O' 2 nt nt 82.1 ± 6.0“ 82.2 ± 7.0” 55.3 ± 5.7”
Benzamil 3x1 O' 5 nt nt nt 63.5 ±18.9* 11.5 ±3.4
N.B.
concentration of 1x10'5M used, nt = not tested. Data represent mean ± s.e.m. 
of 3-4 separate experiments, * denotes p<0.05, ** denotes p<0.005.
Chelation of extracellular Ca2+ using EGTA (4mM), prior to the addition of C5a 
caused 34.7 ± 3.9 % inhibition (p<0.05) of the initial peak increase in [Ca2+]j 
(figure 16A). More detailed analysis of the data, comparing area under the curve 
(AUC) at different time points (figure 16B), revealed that during the first 30 
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Figure 16
(A) Effect of EGTA on C5a-induced Ca2+ mobilisation compared with a vehicle- 
treated control response. (B) Analysis of the effect of EGTA (4mM) was made 
by measuring "area under the curve" (AUC) at early time points (0 to 30 
seconds) and at later time points (30 to 100 seconds), after the addition of C5a 
(30nM). (C) Graphical representation of the effect of EGTA (4mM) against the 
peak increase in [Ca2 +]j, 0"2, LTC4  and ECP release. Data are mean ± s.e.m. of 
4-6 separate experiments; * denotes p < 0.05; ** denotes p < 0.005.
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by 33.9 ± 5.7% (p<0.005), which was almost identical to the inhibition of the 
peak increase in Ca2+. In contrast, the AUC between 30 seconds and 100 
seconds (AUC 30-100 seconds) was markedly inhibited (72.2 ± 8.9 %, p<0.005). 
These data suggest that the C5a-induced transient peak [Ca2+]j elevation 
response and AUC 0-30 seconds was predominantly due to release of Ca2+ from 
intracellular stores, whereas the sustained increase in [Ca2+]j (AUC 30-100 
seconds) was mainly due to Ca2+ influx across the plasma membrane. EGTA 
also caused marked inhibition of O2  and LTC4  release, indicating a requirement 
for extracellular Ca2+ for these responses (figure 16C). In contrast, C5a-induced 
ECP release was not inhibited by 3mM EGTA.
Having established a requirement for extracellular Ca2+ for O2  and LTC4  release, 
the pathway for Ca2+ influx was investigated. The mechanism of activation of 
Ca2+ influx in neutrophils is known to be via depletion of intracellular stores 
(Montero et a!., 1991; Demaurex et al., 1994). It was therefore useful to 
compare the concentration-effect curves to C5a and evaluate whether release 
of intracellular stores correlated with Ca2+ influx. Measurement of C5a-induced 
peak increase in [Ca2+1 and AUC 0-30 seconds appears to predominantly 
represent release of Ca2+ from intracellular stores. The concentration-effect 
curves for these responses were almost identical, with EC5 0  values of 0.36 (0.02- 
6.2) nM and 0.22 (0.06-0.76)nM, respectively (Figure 17A). Similarly, the 
concentration-effect curves for Mn2+ influx and AUC 30-100 seconds were 
comparable, with EC5 0  values of 0.09 (0.02-0.46) and 0.13 (0.07-0.25) nM, 
respectively (Figure 17B). Therefore, it appears that C5a-induced intracellular
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(A) Comparison of C5a-induced Ca2+ responses measured as either area under 
the curve (AUC) between 0 and 30 seconds after agonist addition or peak 
increase in [Ca2+]j and (B) shows a comparison of C5a-induced Ca2+ responses 
measured as area under the curve (AUC) between 30 and 100 seconds after 
agonist addition and rate of Mn2+ influx. Data are represented as mean ± s.e.m. 
of 4 separate experiments.
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Ca2+ release and Ca2+ influx occured at similar concentrations and that Mn2+ 
influx correlated closely with Ca2+ influx, when measured as AUC 30-100 
seconds.
The inorganic cation Ni2+ (3mM), which blocks both RMCE and VOCs, caused 
marked inhibition of the rise in [Ca2 +]j, Mn2+ influx, Oj, LTC4  and ECP responses 
produced by C5a (30nM) (figure 18). However, some inhibition of the Ca2+ 
mobilisation response may be partly due to a small quench of fura- 2  
fluorescence, which was observed upon addition of NiCI2  to the cells. The potent 
and selective VOC blocker, nifedipine (10pM), was inactive against either IP3  
release (18.1 ± 20.8 % inhibition, p>0.05, n=3), Ca2+ elevation or Mn2+ influx 
responses to C5a (figure 19) and at a concentration of 3pM had little or no effect 
against Oj, LTC4  or ECP release. Similarly, diltiazem and verapamil, which 
represent different structural classes of VOC blocker also had little effect against 
Oj, LTC4  and ECP release. The putative RMCE blocker, SK&F 96365 (30pM) 
had no significant effect on IP3  generation (35.7 ±31.1 % enhancement, p>0.05, 
n=4) or the Ca2+ mobilisation response (figure 20A), but caused marked inhibition 
of Mn2+ influx (IC 5 0  = 19.0 (13.7 - 26.4) pM, figure 20B). Furthermore, SK&F 
96365 (30pM) abolished the release of Oj and LTC4  (figure 20C) as did its 
analogue, econazole, whereas ECP was only moderately reduced by SK&F 
96365. Similarly, depolarisation of the cell membrane using KCI caused marked 
inhibition of Oj and LTC4  release, but only caused just over 50% inhibition of 
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(A) Effect of the inorganic cation Ni2+ (3m M ) on C5a-induced C a2+ mobilisation 
and (B) on Mn2+ influx. Cells were pre-treated for 1 minute with either vehicle or 
NiCI2  before addition of C5a (30nM ) and MnCI2 (1m M) was added 1 minute after 
the addition of C5a. (C) Graphical representation of these responses, as well as 
0 2, LTC 4 and EC P release. Data are mean ± s.e.m . of 4 -6  separate  
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Figure 19
(A) Effect of the selective V O C  blocker nifedipine (10pM ) on C5a-induced C a2+ 
mobilisation and (B) on M n2+ influx. Cells were pre-treated for 1 minute with 
either vehicle or nifedipine, before addition of C5a (30nM ) and MnCI2  (1mM) was  
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Figure 20
(A) Effect of the RMCE and VOC blocker, SK&F 96365 on C5a-induced Ca2+ 
mobilisation and (B) on Mn2+ influx. Cells were pre-treated for 1 minute with 
either vehicle or SK&F 96365 before addition of C5a (30nM) and MnCI2  (1mM) 
was added 1 minute after the addition of C5a. (C) Graphical representation of 
these responses, as well as IP3, 0 2, LTC4  and ECP release. Data are mean ± 
s.e.m. of 4-6 separate experiments; * denotes p < 0.05; ** denotes p < 0.005.
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It is clear from these results that C5a stimulates release of intracellular Ca2+ and 
Ca2+ influx. The influx response appears to be mediated via RMCE, rather than 
VOCs and is required for the generation of 0 2  and LTC4. However, conflicting 
results seem to occur with ECP release. Chelation of extracellular Ca2+ by 
EGTA did not inhibit the response, whereas the Ca2+ influx blocker NiCI2  caused 
marked inhibition and SK&F 96365 moderate inhibition. The possibility that 
EGTA may affect the antibody binding in the ECP assay was tested, by carrying 
out the ECP standard curve in the presence and absence of EGTA, but was 
found to have no effect on the curves (data not shown). Another possibility was 
that the concentration of EGTA used was insufficient to chelate all of the 
extracellular Ca2+. C5a-induced ECP release was therefore measured in cells 
resuspended in Ca2+-free HBSS, which had different concentrations of CaCI2  
added to it. Using this protocol ECP release was reduced by 49.0 ± 7.2% 
(p<0.05, n=4) in the presence of 0.3mM CaCI2  compared with the response 
obtained in 1.3mM CaCI2. Based upon this result and the data obtained with the 
Ca2+ influx blockers there is evidence that the C5a-induced ECP response does 
have some extracellular Ca2+ dependence, however it is clearly less dependent 
on extracellular Ca2+ than either 0 2  or LTC4  release.
The presence of cytochalasin B in the 0 2, LTC4and ECP assays may have had 
an effect on their Ca2+ dependence and was therefore investigated. 
Cytochalasin B (5.5pM) had little or no effect (18.1 ± 9.3% enhancement, 
p>0.05, n=4) on the C5a-induced peak increase in [Ca2+]j (Figure 21A). 
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Figure 21
(A) Effect of cytochalasin B on C5a-induced C a2+ mobilisation compared with a 
vehicle-treated control response and (B) a comparison of the C5a-induced C a2+ 
mobilisation response in the presence and absence of EGTA, in cytochalasin B- 
treated cells.
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30.0 % inhibition, p>0.05, n=3), suggesting that cytochalasin B had no effect on 
intracellular Ca2+ release. Measurement of AUC revealed that cytochalasin B 
caused enhancements of 21.8 ± 14.1% (AUC 0-30 seconds, p>0.05, n=4) and 
90.7 ± 42.1 % (AUC 30-100 seconds, p>0.05, n=4). Thus, there appears to be 
a trend towards enhancement of Ca2+ influx in the presence of cytochalasin B, 
but this was variable and did not achieve statistical significance. Addition of 
EGTA (4mM) to cytochalasin B-treated cells caused a similar inhibition of the 
Ca2+ mobilisation response as was seen in the absence of cytochalasin B (Figure 
21B).
4.2.2 Investigation of the second messengers involved in C5a-induced 
eosinophil activation
Investigation of the second messengers that might be involved in C5a-induced 
eosinophil activation was carried out using a range of agents which modulate 
second messengers; mean data are shown in table 8  and are represented 
graphically in figures 22 and 23.
Activation of heterotrimeric G proteins by NaF had no significant effect on C5a- 
induced LTC4  release, but did cause partial inhibition of ECP release. 
Suggesting that there may be differences in the regulatory processes for these 
two responses.
The putative inhibitor of PLC-dependent processes, U73122 (1pM), inhibited 
C5a-induced IP3  generation (66.0 ± 16.3 %, p<0.05, n=3), Ca2+ mobilisation 
(89.3 ± 0.2 %, p<0.005, n=3, figure 23A) and Mn2+ influx (73.1 ±11.8 %, p<0.05,
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Control IP3 [Ca2*], 0 2* LTC4 ECP
Figure 23
(A) Effect of the inhibitor of PLC-dependent process, U73122 on C5a-induced 
Ca2+ mobilisation and (B) Mn2+ influx, compared with a control response. Cells 
were pre-treated for 1 minute with either vehicle or U73122 before addition of 
C5a (30nM) and MnCI2  (1mM) was added 1 minute after the addition of C5a and 
(C) graphical representation of these responses, as well as IP3, 0 2, LTC4  and 
ECP release. Data are mean ± s.e.m. of 3-5 separate experiments; * denotes 
p < 0.05; ** denotes p < 0.005.
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n=3, figure 23B). Similarly, the release of O2  and LTC4  was markedly inhibited 
by U73122 (figure 23C). C5a-induced ECP release was significantly, but only 
partially inhibited by U73122. In contrast, U73343 (1pM), was without effect, 
suggesting some specificity of action. Thus, the 0~2 and LTC4  responses appear 
to mediated predominantly via PLC-dependent processes, whereas ECP release 
requires activation of additional pathway(s).
Table 8 . Effect of agents that modulate second messengers, on C5a-induced 
0'2, LTC4  and ECP release.
Inhibitor Cone
(M)





NaF 2x1 O' 2 nt 31.8 ±19.9 56.5 ± 2.1**
U73122 1 x 1  cr6 98.1 ± 0.9** 91.4 ±3.4** 46.2 ± 7.6**
U73343 Ix lO - 6 9.6 ±7.6 14.4 ±17.3 8 . 1  ± 8 . 0
Wortmannin 1x1 O' 8 nt $8 6 . 6  ± 2 . 2 21.2 ±6 .5
Wortmannin 1x1 O' 6 nt $92.8 ± 3.7 92.7 ± 2.4**
Forskolin 3x1 O' 5 29.5 ±15.9 15.1 ±30.1 -8.5 ± 5.6
Rolipram 1 x 1 0 ‘ 7 92.4 ±4.0** 91.0 ±7.0* #13.3 ± 10.0
Nitroprusside 1x1 O' 6 -8 . 6  ±6.9 -28.5 ± 38.5* -11.3 ±7.1
PMA
00OXr- nt 79.8 ±10.3** 66.4 ± 3.2**
Bisindolymaleimide 1x1 O' 7 -4.7 ±3.6 -26.4 ± 37.5 42.8 ± 4.8**
Erbstatin analogue 1x1 O' 5 nt 71.6 ±21.0* 79.9 ± 7.6**
Calyculin A 1x1 O' 7 nt 89.6 ± 6.5** 9.4 ± 8.0
Okadaic acid 1x1 O' 6 nt $88.7 ± 5.0 19.9 ± 6 .7
Cyclosporin A 1x1 O*6 nt $-72.7 ± 51.7 11.3 ±8 .2
# denotes rolipram concentration of 3x1 O^M used, nt = not tested. $ denotes 
mean ± s.d. of n= 2  separate experiments, otherwise data represent mean ± 
s.e.m of 3-6 separate experiments, * denotes p<0.05, ** denotes p<0.005.
Further differences between C5a-induced LTC4  and ECP release were observed 
with wortmannin. At a concentration of 10nM, inhibition of LTC4, but not ECP
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release was observed. However, at a concentration of 1|jM, wortmannin 
inhibited both LTC4  and ECP release. This suggests that the LTC4  response 
involves activation of PI-3 kinase, whereas ECP does not involve PI-3 kinase, 
but may involve activation of tyrosine kinase and/or PLD.
Elevation of cAMP by forskolin had no significant effect on 0 2, LTC4  or ECP 
release. In contrast, inhibition of PDE IV activity by rolipram, abolished release 
of 0 '2  and LTC4, but had no effect on ECP. This once again suggests that there 
is a difference in the regulatory processes which control 0 2  and LTC4  compared 
with ECP release. The difference in effectiveness of forskolin and rolipram, may 
suggest that the phosphodiesterase enzymes present in eosinophils are very 
active and rapidly breakdown cAMP, therefore inhibition of breakdown of cAMP 
would be a more effective means of elevating the level of cAMP in the cell.
Elevation of cGMP by sodium nitroprusside had no significant effect on 0 2  or 
ECP release, but did appear to cause a modest enhancement of LTC4  release.
Activation of PKC by PMA (10nM) had no significant effect (29.7 ± 21.5 % 
inhibition, p>0.05, n=6 ) on the peak increase of [Ca2+]j (figure 24A), but caused 
marked inhibition of both LTC4  and ECP release (figure 24B). PMA (10nM) 
alone caused substantial 0 2  release (16.4 ± 1.1 nmoles cytochrome C/2.5x105  
eosinophls/10 minutes, n=4). Inhibition of PKC, by bisindolymaleimide had no 
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Figure 24
(A) Effect of the PKC activator, PMA on C5a-induced C a2+ mobilisation and (B) 
graphical representation of this response, as well as LTC 4  and ECP release. 
Data are mean ± s.e.m . of 4 -6  separate experiments; * denotes p < 0.05; ** 
























Control [Ca2+]j LTC4 ECP
(A) Effect of the tyrosine kinase inhibitor, erbstatin analogue on C5a-induced  
C a2+ mobilisation and (B) graphical representation of this response, as well as 
LTC4 and ECP release. Data are m ean ±  s.e.m. of 3-4 separate experiments; 
* denotes p < 0.05; ** denotes p < 0.005.
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No significant inhibition of the peak increase of [Ca2+]j (figure 25A) was observed 
with the erbstatin analogue (3pM). Activation of tyrosine kinase did appear to 
be a common requirement for both LTC4  and ECP release, as the erbstatin 
analogue inhibited both these responses (figure 25B), with IC5 0  values of <1pM 
(93.0 ± 6.4 % inhibition at 1pM, p<0.005, n=4) and 1.71(0.8 - 3.5) pM, 
respectively.
Investigation of the effect of phosphatase inhibitors found that calyculin A and 
okadaic acid inhibited LTC4  release, with IC5 0  values of 17.8 (1.8 -176) nM and 
0.29 (0.11 - 0.76) pM, respectively. The low potency of okadaic acid compared 
with calyculin suggested that PP1 rather than PP2A was involved in the 
responses. In contrast, these agents had no effect against ECP release. The 
PP2B inhibitor, cyclosporin A had no effect against either LTC4  or ECP release. 
In summary, C5a-induced 0~2 and LTC4  release appear to be predominantly 
mediated via a PLC-dependent pathway. LTC4  release involves activation of Pl- 
3 kinase and tyrosine kinase, as well as PP1. In addition, activation of PKC and 
elevation of cAMP inhibited LTC4  release. ECP release appears to be partially 
dependent upon PLC activation, but may also require tyrosine kinase and/or 
PLD activation and like LTC4  release, involves stimulation of tyrosine kinase. 
Finally, ECP release was inhibited both by inhibition and activation of PKC.
4.2.3 Investigation of the effect of pertussis toxin (PTX) pre-treatment on 
C5a-induced eosinophil activation
Pretreatment of human eosinophils with PTX (0.2, 1 and 2 pg/ml: 90 minutes, 
37°C, 107  cells/ml) caused a concentration-dependent inhibition of C5a-induced
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increase in [Ca2+]j (figure26A). PTX pre-treatment (1pg/ml) reduced the increase 
in [Ca2+]j by 78.0 ± 13.1 % (p<0.005, n=4) and caused 43.9 ± 7.7 % (p<0.005, 
n=4) inhibition of C5a-induced Mn2+ influx (figure 26B). Similarly, concentration- 
effect curves to C5a, for ECP release were also inhibited by PTX pretreatment 
(figure 27A). PTX pretreatment (1pg/ml) caused 81.1 ± 9.9 % inhibition 
(p<0.005, n=4) of C5a (30nM)-induced ECP release. Comparison of the level 
of Ca2+ mobilisation and ECP release, with increasing concentrations of PTX 
revealed a close correlation between the degree of inhibition seen against these 
responses (figure 27B). This suggests that C5a mediates its effects via a PTX- 
sensitive Gr like G protein and that this G protein is common for both Ca2+ and 
ECP responses.
4.2.4 Investigation of the effect of selected pharmacological reference 
agents on C5a-induced eosinophil activation
A range of pharmacological reference agents which possess anti-inflammatory 
activity or are used in asthma therapy, were tested for their effects against C5a- 
induced 0 2, LTC4  and ECP release in human eosinophils; mean data are shown 
in table 9.
The p2-agonist salbutamol, the potassium channel opener cromakalim, the 
histamine antagonist cetirizine, as well as sodium cromoglycate had no 
significant effect on the C5a-induced release of 0 2, LTC4  or ECP release. The 
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Figure 26
(A) Effect of the PTX pre-treatment on C5a-induced Ca2+ mobilisation and (B) 
Mn2+ influx, compared with a control response. Cells were pre-treated for 90 
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(A) Effect of the PTX pre-treatment on C5a concentration-effect curves for ECP 
release and (B) comparison of inhibition of C5a (30nM)-induced Ca2+ 
mobilisation and ECP release. Cells were pre-treated for 90 minutes at 37°C, 
with either vehicle or PTX. Data are mean ± s.e.m. of 4 separate experiments; 
* denotes p < 0.05; ** denotes p < 0.005.
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although this was not statistically significant, as well as a very small inhibition of 
ECP release.
Table 9. Effect of anti-asthma/anti-inflammatory agents, on C5a-induced O2 , 
LTC4  and ECP release.
% Inhibition of C5a-induced responses
(Mean ± s.e.m.)
Inhibitor Cone
0~2 release l t c 4 ECP
(M) release release
Cetirizine 1x1 O' 5 7.1 ±9.0 0.5 ± 24.4 6.5 ± 4.0
Cromakalim 1x1 O' 5 -4.5 ±5.1 18.6 ± 14.2 8.7 ±4 .3
Sodium cromoglycate 1x1 O’ 6 -3.4 ± 5.8 -7.3 ±16.3 nt
Salbutamol 1x1 O' 6 7.0 ± 5.2 6.4 ± 30.6 2.9 ±4 .5
WEB 2086 1x1 O' 5 nt 56.5 ± 18.9 15.1 ±2.7**
Indomethacin 3x1 O' 6 18.9 ±10.5 68.1 ± 10.5** 3.8 ± 9.2
BAY x1005 1x1 O' 5 nt 88.2 ± 7.4** 7.8 ± 10.8
Data represent mean ± s.e.m of 3- 6  separate experiments, nt = not tested.
* denotes p<0.05, ** denotes p<0.005.
The COX inhibitor, indomethacin was without effect against either O2  or ECP 
release, but was effective at inhibiting LTC4  release. This may suggest that C5a 
stimulated synthesis of prostanoids which were stimulatory for leukotriene 
generation. The LSI, Bay x1005 selectively abolished the release of LTC4, whilst 
having no effect on ECP release.
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4.3 Thapsigargin-induced human eosinophil activation
4.3.1 Investigation of the role of Ca2+ in thapsigargin-induced eosinophil 
activation.
A range of agents which modulate Ca2+-dependent effects were tested against 
thapsigargin-induced LTC4  release (in the absence of cytochalasin B); mean 
data are shown below in table 1 0 .




% Inhibition of thapsigargin- 
induced LTC4  release
Mean ± SEM
EGTA 3x1 O' 3 97.9 ± 0.8**
NiCI2 3x10 3 88.3 ± 3.6**
SK&F 96365 X o cn 92.5 ± 2.8**
Nifedipine 3x1 O' 6 22.9 ±15.3
Diltiazem 1x1 O' 5 -17.8 ±10.4
Verapamil 1x1 O' 5 -5.3 ± 3.3
KCL 5x1 O’ 2 67.3 ±10.3*
Benzamil 3x1 O' 5 -124.9 ± 40.2*
Data represent mean ± s.e.m. of 4-8 separate experiments, * denotes p<0.05, 
** denotes p<0.005.
Addition of the Ca2+ chelating agent, EGTA caused concentration-dependent 
inhibition of thapsigargin-induced LTC4  release, with a mean IC5 0  value of 0.28 
(0.20 - 0.39) mM. This indicated that these responses required extracellular 
Ca2+. Investigation of the type of Ca2+ influx pathway involved in thapsigargin - 
induced LTC4  production, revealed an identical profile to that seen with C5a- 
induced LTC4  release. The RMCE blockers NiCI2  (3mM) and SK&F 96365
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(30|jM) inhibited the thapsigargin-induced Ca2+ influx response, in fura-2 -loaded 
cells, by 98.9 ± 0.8 % (p<0.005, figure 28A) and 69.4 ± 11.0 % (p<0.05, figure 
29A). Furthermore, both NiCI2  and SK&F 93365 also caused concentration- 
dependent inhibition of thapsigargin-stimulated LTC4  release, with mean IC5 0  
values of 0.09 (0.04 - 0.18) mM (figure 28B) and 3.0 (2.5 - 3.5) pM (figure 29B), 
respectively. In contrast, the VOC blockers nifedipine, diltiazem and verapamil 
were without effect against thapsigargin-mediated LTC4  release. Additionally, 
membrane depolarisation by KCI also caused marked inhibition of leukotriene 
generation. Thus, RMCE rather than VOC-mediated Ca2+ entry is necessary for 
thapsigargin-induced LTC4  release.
The Na+/Ca2+ exchange inhibitor, benzamil (30pM) differed in its inhibitory profile 
against C5a and thapsigargin, as it inhibited C5a-induced LTC4  release, but 
enhanced the response to thapsigargin.
4.3.2 Investigation of the second messengers involved in thapsigargin- 
induced eosinophil activation.
Investigation of the second messengers that might be involved in thapsigargin- 
induced eosinophil activation was carried out using a range of agents which 
modulate second messengers; mean data are shown in table 1 1 .
Addition of U73122 (1pM), prior to the addition of thapsigargin caused marked 
inhibition (80.6 ± 6 . 8  %, n=2) of the Ca2+ influx response (figure 30A). In 
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(A) Effect of NiCI2  on thapsigargin-induced Ca2+ influx and (inset) graphical 
representation of this response (n=2). (B) Concentration-dependent inhibition 
of thapsigargin-induced LTC4  release by NiCI2. Data are mean ± s.e.m. of 8  
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Figure 29
(A) Effect of SK&F 96365 (30|jM) on thapsigargin-induced Ca2+ influx and (inset) 
graphical representation of this response (n=3). (B) Concentration-dependent 
inhibition of thapsigargin-induced LTC4  release by NiCI2 (n=8 ). Data are mean 
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(A) Effect of U 73122 (1pM ) (dashed line) on thapsigargin-induced C a2+ influx 
added 1 minute before thapsigargin or (B) added 1 minute after thapsigargin 
addition. Traces are representative of 2 separate experiments.
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caused 31.3 ± 27.1 % (n=2) inhibition. This suggests that U73122 has an effect 
on the depletion process, rather than an effect on Ca2+ influx. U73122 (1pM) 
caused 99.5 ± 0.5 % inhibition (n=2) of LTC4  release (in the presence of 
cytochalasin B), whereas U73343 (1pM) caused only 10.6 ± 36.2 % inhibition, 
suggesting some specificity of action.
Table 11. Effect of agents that modulate second messengers, on thapsigargin- 
induced LTC4  release.
Inhibitor Concentration
(M)
% Inhibition of thapsigargin- 
induced LTC4  release
Mean ± s.e.m.
NaF 2x1 O' 2 77.4 ± 6.1**
Forskolin 3x1 O' 5 -66.0 ± 26.9
Rolipram 3x1 cr6 58.0 ± 8 .8 **
Nitroprusside 1x1 O' 6 9.9 ±4 .7
PMA 1x1 O’ 8 -16.6 ±23.5
R59022 1 x1 0 * 5 76.0 ± 2.7**
Bisindolymaleimide 1x1 O' 6 -256.8 ±136.8
Erbstatin analogue 3x1 O' 6 99.0 ± 0.6**
Calyculin A 1x1 O' 7 68.9 ± 14.3*
Data represent mean ± s.e.m. of 4-5 separate experiments, ’ denotes p<0.05, 
** denotes p<0.005.
Activation of heterotrimeric G proteins by NaF caused a significant reduction of 
thapsigargin-induced LTC4  release, suggesting that it may be possible to activate 
inhibitory G proteins and so inhibit the effects of thapsigargin.
Elevation of cAMP by forskolin or cGMP by sodium nitroprusside had no 
significant effect on LTC4  generation. In contrast, inhibition of PDE IV activity by 
rolipram, caused marked inhibition of release of LTC4.
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Activation of PKC, by PMA caused marked inhibition of the Ca2+ influx response, 
whether it was added before (61.2 ± 20.6 %) or after (73.0 ± 17.7 %) the addition 
of thapsigargin. This suggests that PMA was exerting its effects distal to the 
depletion of intracellular Ca2+ stores. However, somewhat surprisingly PMA had 
no effect against LTC4  release; particularly since the diacylglycerol (DAG) 
kinase inhibitor R59022, which would also activate PKC, did cause substantial 
inhibition of thapsigargin-induced LTC4  release. Furthermore, inhibition of PKC 
by bisindolymaleimide caused a trend towards enhancement of leukotriene 
generation.
In common with C5a-induced LTC4  release, the thapsigargin-mediated 
responses were concentration-dependently inhibited by the tyrosine kinase 
inhibitor, erbstatin analogue and the phosphatase inhibitor, calyculin with IC5 0  
values of 0.39 (0.19 - 0.82) pM and 65.5 (39.3 - 109) nM, respectively.
In summary, thapsigargin appears to cause depletion of intracellular Ca2+ stores 
via a PLC-dependent pathway and stimulated a Ca2+ influx response which is 
inhibited by activation of PKC. Leukotriene generation may be inhibited by 
activation of an inhibitory G protein, as well as by elevation of cAMP via inhibition 
of PDE IV. Finally, thapsigargin-induced LTC4  release involves activation of 
tyrosine kinase as well as PP1 (and/or PP2A).
4.3.3 Investigation of the effect of pertussis toxin (PTX) pretreatment on 
thapsigargin-induced eosinophil activation.
PTX pretreatment of human eosinophils had only a small inhibitory effect
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(29.8 ± 3.3 %, p<0.005, n=4) on the thapsigargin-induced increase in [Ca2+]j and 
had no effect (-22.1± 24.2 % inhibition, p>0.05, n=3) on the Mn2+ influx response 
(figure 31). This suggests that thapsigargin-induced Ca2+ influx is not 
predominantly mediated via a PTX-sensitive G protein, nor is there activation of 
a tonic inhibitory PTX-sensitive G protein, as there was no enhancement of 
thapsigargin-induced Ca2+ influx.
4.3.4 Investigation of the effect of selected pharmacological reference 
agents on thapsigargin-induced eosinophil activation
A range of pharmacological reference agents which possess anti-inflammatory 
activity or are used in asthma therapy, were tested for their effects against 
thapsigargin-induced LTC4  generation in human eosinophils; mean data are 
shown below in table 1 2 .
Table 12. Effect of anti-asthma/anti-inflammatory agents, on thapsigargin- 
induced LTC4  release.
Inhibitor Concentration
(M)
% Inhibition of thapsigargin- 
induced LTC4 release
Mean ± s.e.m.
Cetirizine 1x1 O' 5 -44.2 ± 7.7*
Cromakalim 1x1 O' 5 -65.0 ± 7.2**
Salbutamol 1x1 O' 6 -53.2 ±17.9
Indomethacin 3x1 O' 6 9.6 ±9 .3
BAY x1005 1x1 O' 5 96.3 ±1.3**
WEB 2086 1x1 O' 5 -50.9 ± 9.6*
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Figure 31
(A) Effect of the PTX pre-treatm ent on thapsigargin-induced C a2+ influx, with 
graphical representation of this response inset (n=4) and (B) effect of PTX pre­
treatm ent on M n2+ influx, compared with a control response. Cells w ere pre­
treated for 90 minutes at 37°C, with either vehicle or PTX. Traces are 
representative of 3-4 separate experiments are mean ± s.e.m. of 4 separate  
experiments; * denotes p < 0.05; ** denotes p < 0.005.
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The p2-agonist salbutamol, the potassium channel opener cromakalim, the 
histamine antagonist cetirizine, as well as the PAF antagonist WEB 2086 caused 
enhancement of thapsigargin-induced LTC4  release. The COX inhibitor, 
indomethacin was without effect, whilst the LSI, Bay x1005 abolished the release 
of LTC4.
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4.4 FMLP-induced human eosinophil activation
4.4.1 Investigation of the role of Ca2+ in FMLP-induced eosinophil 
activation.
A range of agents which modulate Ca2+-dependent effects were tested against 
FMLP-induced eosinophil activation; mean data are shown below in table 13.
Table 13. Effect of agents that modulate Ca2+ influx, on fMLP-induced 0 2, LTC4  
and ECP release.
Inhibitor Cone(M)
% Inhibition of FMLP-induced 
responses (Mean ± s.e.m.)
Oj release l t c 4release
ECP
release
EGTA 3x1 O' 3 74.6 ±10.1* 94.5 ± 2.4** 7.9 ± 15.9
NiCI2 3x1 O' 3 41.9 ±10.8** 83.1 ± 3.8** 21.7 ±15.0
SK&F 96365 3x10 ‘ 5 63.8 ± 6.0** 90.3 ± 3.2** 3.4 ±10.6
Nifedipine 3x10*6 -0.5 ± 6 . 6 8.0 ± 16.3 0.6 ±15.5
Diltiazem 3x1 O' 6 18.6 ±7 .7 38.8 ±12.5* #5.5 ± 15.8
Verapamil 3x1 O' 6 17.1 ±4.9* 36.9 ± 14.2* #-8.2 ± 17.4
KCI 5x10 ‘ 2 69.5 ± 9.7** 64.1 ± 17.6* 32.2 ±21.3
Benzamil 3x1 O' 5 nt -64.8 ± 25.2 -21.1 ±17.7
# denotes inhibitor concentration of 1x10'5M used. Data represent mean ± sem 
of 4-10 separate experiments, * denotes p<0.05, ** denotes p<0.005.
EGTA (3mM) caused concentration-dependent inhibition of and LTC4  release, 
with mean IC5 0  values of 0.75 (0.48 - 1.2) mM and 0.58 (0.47 - 0.73) mM, 
respectively, indicating a requirement for extracellular Ca2+ for these responses 
(figure 32A). In contrast, FMLP-induced ECP release was not inhibited by 
EGTA, up to a concentration of 3mM.
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Having established a requirement for extracellular Ca2+ for 0 2  and LTC4 release, 
the pathway for Ca2+ influx was investigated. NiCI2  caused concentration- 
dependent inhibition of 0 2  release, with an IC5 0  value of 3.6 (1.3 - 9.7) mM and 
caused marked inhibition of LTC4  release (figure 32B) with an IC5 0  < 0.1 mM 
(71.5 ± 10.8 % inhibition at 0.1 mM, p<0.005). Similarly, SK&F 96365 caused 
inhibition of 0 2  and LTC4  release in a concentration-dependent manner, with 
mean IC5 0  values of 16.0 (12.1 -21.1) pM and 11.0 (7.8 -15.7) pM, respectively 
(figure 32C). In contrast, FMLP-induced ECP release was not inhibited by either 
NiCI2  or SK&F 96365, providing further evidence that this response was not 
dependent upon Ca2+ influx. Furthermore, addition of KCI markedly inhibited 0 2  
and LTC4  release, but had no significant effect on ECP release. The VOC- 
blocking agents nifedipine, diltiazem and verapamil had little or no effect on 0 2, 
LTC4  or ECP release. Although there was some inhibition of LTC4  release by 
diltiazem and verapamil at 3pM, no further inhibition was seen with a higher 
concentration. Finally, benzamil had no significant effect on FMLP-mediated 
LTC4  and ECP release, although there was a trend towards enhancement of 
leukotriene release, which was similar to its effects on thapsigargin.
4.4.2 Investigation of the second messengers involved in FMLP-induced 
eosinophil activation.
Investigation of the second messengers that might be involved in FMLP-induced 
eosinophil activation was carried out using a range of agents which modulate 
second messengers; mean data are shown in table 14 and are represented 
graphically in figure 33.
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(A) The effect of increasing concentrations of EGTA, (B) NiCI2 and (C) SK&F  
96365 on FMLP-induced 0 2, LTC4 and ECP release in human eosinophils. Data 
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Figure 33
(A) Effect of agents which modulate second messengers, on FMLP-induced 
LTC4  release and (B) ECP release. Wortmannin and okadaic acid data are 
mean ± s.d. of 2  separate experiments, otherwise data represent mean ± s.e.m 
of 4-10 separate experiments, * denotes p<0.05, ** denotes p<0.005.
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Activation of heterotrimeric G proteins by NaF had a marked inhibitory effect on 
FMLP-induced LTC4  release, but did not cause any inhibition of ECP release.
Table 14. Effect of agents that modulate second messengers, on fMLP-induced 
O2 , LTC4  and ECP release.
Inhibitor Cone
(M)
% Inhibition of FMLP-induced 
responses (Mean ± s.e.m.)
Oj release LTC4release ECP release
NaF 2x1 O' 2 nt 71.1 ±5.8" 19.5 ± 17.2
U73122 1x1 O' 6 92.1 ± 2.9” 66.4 ±10.5" 20.5 ± 11.5
U73343 1x1 O’ 6 7.8 ±6 .9 10.5 ±12.9 1 . 0  ± 1 1 . 2
Wortmannin 1 x1 0 -® nt $42.2 ± 6.2 33.3 ±19.5
Wortmannin 1 x 1 0 * nt $97.5 ± 2.5 84.1 ±10.3*
Forskolin 3x10‘ 5 41.7 ±12.4 -12.2 ±15.0 -9.0 ± 12.9
Nitroprusside 1 x 1 0 * 13.2 ±6 .5 -71.0 ±34.9 -23.7 ±11.8
PMA 1 x1 0 * nt 78.3 ± 7.5" 65.8 ± 5.6*
Bisindoly maleimide 1 x1 0 * nt -49.4 ± 29.3 47.5 ± 26.2
Erbstatin analogue X p (In nt 96.4 ± 0.8" 94.7 ±1.2"
Calyculin A 1x1 O' 7 nt 80.5 ± 9.9" 39.6 ± 20.4
Okadaic acid 1 x 1 0 * nt $86.3 ± 2.2 34.5 ±13.0
Cyclosporin A 1 x 1 0 * nt *13.9 ± 12.1 -13.0 ±11.9
N.B. $ denotes mean ± s.d. 0 1 f n= 2  separate experiments, otherwise data
represent mean ± s.e.m of 4-10 separate experiments, * denotes p<0.05, " 
denotes p<0.005.
FMLP-induced ECP release was not inhibited by U73122 (1 pM), whereas O2  and 
LTC4  release were substantially inhibited. U73343 (1pM) was without effect 
against any of the responses, suggesting some specificity of action. Thus the 
Oj and LTC4  responses appear to be mediated predominantly via PLC- 
dependent processes, whereas ECP release requires activation of a different 
path way (s).
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Wortmannin caused marked inhibition of both LTC4  and ECP release at a 
concentration of 1pM, but not at 10nM. This contrasts with the more potent 
effects of wortmannin against C5a-induced leukotriene generation, and suggests 
that FMLP-mediated effects may have a greater-dependence on tyrosine kinase 
and/or PLD activation, rather than PI-3 kinase.
The cAMP and cGMP elevators, forskolin and sodium nitroprusside had no 
significant effect on any of the responses, which was consistent with the data 
obtained for C5a-induced responses.
Activation of PKC by PMA markedly inhibited LTC4  release and inhibition of PKC 
by bisindolymaleimide caused some enhancement of leukoriene generation, 
although this was not statistically significant. FMLP-induced ECP release was 
reduced by both activation and inhibition of PKC. This paradoxical effect was 
also seen with C5a-induced ECP release.
Activation of tyrosine kinase did appear to be a common requirement for both 
LTC4  and ECP release, as the erbstatin analogue inhibited both these 
responses, with IC5 0  values of 1.1 (0.5 - 2.7) pM and 1.4 (0.9 - 2.2) pM, 
respectively.
Investigation of the effect of phosphatase inhibitors found that calyculin A and 
okadaic acid inhibited LTC4  release, with IC5 0  values of 63.4 (44.7 - 89.9) nM and 
0.21 (0.17 - 0.26) pM, respectively, but had no effect against ECP release. The 
low potency of okadaic acid compared with calyculin suggested that PP1 rather 
than PP2A was involved in leukotriene generation. The PP2B inhibitor,
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cyclosporin A was without effect against either LTC4 or ECP release.
In summary, FMLP-induced O2  and LTC4  release appear to be predominantly 
mediated via a PLC-dependent pathway. LTC4  release also involves activation 
of tyrosine kinase, PP1 and perhaps PLD, whilst activation of PKC inhibited the 
response. ECP release appears to be independent of PLC activation, but may 
be mediated via tyrosine kinase and/or PLD activation. Paradoxically, ECP 
release was inhibited both by inhibition and activation of PKC.
4.4.3 Investigation of the effect of pertussis toxin (PTX) pretreatment on 
FMLP-induced eosinophil activation.
Pretreatment of human eosinophils with PTX (0.2, 1 and 2 pg/ml: 90 minutes, 
37°C, 107  cells/ml) caused concentration-dependent inhibition of fMLP-induced 
increase in [Ca2+]j (figure 34). PTX pretreatment (1 pg/ml) reduced the FMLP- 
mediated increase in [Ca2+]j by 91.2 ± 4.5 % (p<0.005, n=4). Similarly, 
concentration-effect curves to FMLP, for ECP release were also inhibited by PTX 
pretreatment (figure 35A). PTX pretreatment (1 pg/ml) caused 94.2 ± 3.5 % 
inhibition (p<0.005, n=4) of FMLP (IpM)-induced ECP release. Comparison of 
the level of Ca2+ mobilisation with LTC4  and ECP release, using increasing 
concentrations of PTX, revealed a close correlation between degree of inhibition 
seen for these responses (figure 35B). This suggests that FMLP mediated its 
effects via a PTX-sensitive Gr like G protein and that this G protein is common 














(A) Effect of PTX pretreatment on FMLP-induced Ca2+ mobilisation compared 
with a control response. Cells were pretreated for 90 minutes at 37°C, with either 
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Figure 35
(A) Effect of PTX pretreatment on FMLP concentration-effect curves for ECP 
release and (B) comparison of inhibition FMLP (IpM)-induced Ca2+ mobilisation, 
LTC4  and ECP release. Cells were pretreated for 90 minutes at 37°C, with either 
vehicle or PTX. Data are mean ± s.e.m. of 4 separate experiments; * denotes 
p < 0.05; ** denotes p < 0.005.
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4.4.4 Investigation of the effect of selected pharmacological reference 
agents on FMLP-induced eosinophil activation.
A range of pharmacological reference agents which possess anti-inflammatory 
activity or are used in asthma therapy, were tested for their effects against 
FMLP-induced 0"2, LTC4  and ECP release in human eosinophils; mean data are 
shown in table 15.
Table 15. Effect of anti-asthma/anti-inflammatory agents, on fMLP-induced 0 2, 
LTC4  and ECP release.
Inhibitor Cone
(M)
% Inhibition of FMLP-induced 
responses (Mean ± s.e.m.)
0 2  release l t c 4release
ECP
release
Cetirizine 1x1 O' 5 20.3 ± 4.9* -17.9 ±6.9 11.4 ±6.9
Cromakalim 1x1 O' 5 35.4 ±16.1 -5.9 ±15.4 11.9 ± 3.7
Sodium cromoglycate 1x1 O' 6 32.2 ± 20.0 -16.4 ±18.6 nt
Salbutamol 1x1 O' 6 29.0 ± 9.7 -15.3 ±9 .4 1.9 ±13.5
WEB 2086 1x1 O' 5 nt 18.6 ±11.3 8.7± 1.5
Indomethacin 3x10-® 27.3 ± 6 .6 * -0.2 ±15.1 9.2 ±9.1
BAY x1005 1x1 O' 5 nt 99.6 ± 0.4** 34.6 ±18.8
Data represent mean ± s.e.m of 4 separate experiments, * denotes p<0.05, 
denotes p<0.005.
The p2-agonist salbutamol, the potassium channel opener cromakalim, the 
histamine antagonist cetirizine, as well as sodium cromoglycate had no 
significant effect on FMLP-induced release of 0 2, LTC4  or ECP release. The 
PAF receptor antagonist, WEB 2086 and the COX inhibitor, indomethacin had 
little or no effect against LTC4  or ECP release. Finally, the LSI Bay x1005 
selectively abolished the release of LTC4, whilst having no effect on ECP.
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4.5 LTD4-induced human eosinophil activation
4.5.1 Regulation of LTD4-induced increases in [Ca2+]j in human 
eosinophils.
Chelation of extracellular Ca2+ by EGTA (4mM) inhibited the LTD4-induced rise 
in [Ca2+]j by 57.8 ± 21.1 % (p>0.05, n=3; figure 36B), although this did not 
achieve statistical significance. This suggests that a large component of the 
peak increase in cytosolic free Ca2+ was due to Ca2+ influx. Preliminary data 
from a single experiment supported this view, as SK&F 96365 (30pM) and NiCI2  
(3mM) caused 65% and 95% inhibition, respectively of the Ca2+ mobilisation 
response.
Activation of PKC by PMA, caused 87.7 ±11.1 % inhibition (p<0.005, n=5; figure 
36A and B). This was much greater than the effect of PMA against C5a-induced 
elevation of [Ca2+]it but was similar to the inhibition of the thapsigargin-induced 
response.
The potent PP1 inhibitor, calyculin (100nM) reduced the LTD4-mediated Ca2+ 
mobilisation response by 41.6 ± 31.5 % (p>0.05, n=3), but this effect was not 
statistically significant. The tyrosine kinase inhibitor, erbstatin analogue (3pM) 
was without effect (3.4 ±11.1 % inhibition, n=2; figure 36B).
4.5.2 Investigation of the effect of pertussis toxin (PTX) pretreatment on 
LTD4-induced increases in [Ca2+], in human eosinophils.
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Figure 36
(A) Effect of the PKC activator, PMA on LTD4-induced Ca2+ mobilisation and (B) 
graphical representation of this response, as well as the effect of EGTA, 
calyculin and erbstatin analogue on the Ca2+ mobilisation response. Data are 




37°C, 107 cells/ml) caused partial inhibition of LTD4-induced increase in [Ca2+]j 
(figure 37A). PTX pretreatment (1pg/ml) reduced the LTD4-mediated increase 
in [Ca2+]j by 46.1 ± 8.7 % (p<0.005, n=4; figure 37A inset). However, PTX 
pretreatment (1pg/ml) did not appear to have any effect on LTD4-induced Mn2+ 
influx (12.5 ± 24.7 % inhibition, p>0.05, n=4; figure 37B). This contrasts with the 
marked inhibition of C5a- and FMLP-mediated effects and suggests that LTD4  











Control EGTA PMA Calyculin Erbstatin 
4mM 10nM 100nM ana 3^M
Figure 37
(A) Effect of PTX pretreatment on LTD4-induced Ca2+ mobilisation, with graphical 
representation of this data (inset) and (B) Mn2+ influx, compared with a control 
response. Cells were pretreated for 90 minutes at 37°C, with either vehicle or 
PTX. Traces are representative of 4 separate experiments. Graphical data are 
mean ± s.e.m. of 4 separate experiments; * denotes p < 0.05; ** denotes p < 
0.005.
129
5. DISCUSSION AND CONCLUSIONS
5.1 Spontaneous 0~2 release
The finding that eosinophils spontaneously released O2  was initially rather 
perplexing, as it delayed progress in measuring agonist-induced eosinophil 
activation. However, in the process of eliminating this spontaneous activity, it 
became clear that this response had an interesting pharmacological profile.
Dri et al. (1991) reported that eosinophils in contact with ELISA plastic exhibited 
a respiratory burst response. Furthermore, they found that different biological 
surfaces had a profound effect on the ability of eosinophils to release O2  in 
response to a range of physiological stimuli.
Examination of the morphology of the cells in this study, showed that the 
eosinophils were adhering to the plastic surface of microtitre plates and that 
spreading had taken place. In fact, their appearance was remarkably similar to 
that observed by Laudanna et al. (1993a), when they examined eosinophils 
adhered via cross-linking of VLA-4. They also reported similar effects with 
eosinophils adhered via p2 integrins, but not when adhered to anti-class 1 MHC 
antigen-coated plates. Furthermore, cross-linking of VLA-4, LFA-1, CR3 or the 
common p2  chain by immobilised monoclonal antibody also caused activation of 
the eosinophil respiratory burst response.
Thus, it is tempting to speculate that adhesion of the eosinophils to plastic may 
cause cross-linking or a sufficient conformational change in the surface integrins 
of the eosinophil to cause activation. However, the lack of effect of the anti-
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CD11b and CD18 antibodies suggests that CD11b and CD18 integrins were not 
involved in the spontaneous respiratory burst response.
Interestingly, pretreatment of the MTPs with laminin abolished the spontaneous 
superoxide response. Functional laminin (VLA-6 ) receptors are known to be 
expressed on human eosinophils and are believed to be involved in the adhesive 
interaction of eosinophils with extracellular matrix proteins. These matrix 
proteins are present on sub-endothelial basement membranes and on interstitial 
connective tissue (Georas et al., 1993).
Similarly, it seems likely that eosinophils adhered to gelatin, when it was 
included in the buffer. Neutrophils are known to adhere to gelatin (denatured 
collagen), which represents another component of the extracellular matrix 
(Perskin and Cronstein, 1992). During the process of transendothelial cell 
migration to the site of inflammation, eosinophils travel through extracellular 
matrix tissues, en route to the inflammatory site. Therefore, physiologically, it 
would appear to make good sense that in the absence of an inflammatory 
stimulus eosinophils do not exhibit a respiratory burst response when they are 
adhered to the extracellular matrix proteins.
Further circumstantial evidence that the spontaneous respiratory burst response 
was via integrin-mediated activation, was obtained by studying the signal 
transduction processes associated with this activity. Comparison of eosinophil 
O2  release, with integrin-mediated neutrophil activation of the respiratory burst 
response, demonstrated several similarities.
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Firstly, stimulation of neutrophils with anti-CD18, anti-LFA-1 or gp150/95 mAbs 
stimulated a respiratory burst response, which was abolished by the 
microfilament disrupting agent, cytochalasin B (Berton etal., 1992).
Secondly, activation of respiratory burst in human eosinophils, in response to 
antibodies to CD18 and LFA-1, was inhibited by wortmannin and tyrosine kinase 
inhibitors, but not by staurosporine (Laudanna et al., 1993a). This profile of 
inhibition is identical to that observed with the spontaneous activity in human 
eosinophils, in the current study. In another study by Laudanna etal. (1993b), 
wortmannin and tyrosine kinase inhibitors prevented neutrophil spreading. They 
suggested that the process of spreading may be required for integrin-mediated 
generation of 0~2 and that wortmannin may act via inhibition of myosin light chain 
kinase (MLCK). However, it has subsequently been demonstrated that 
wortmannin is an extremely potent inhibitor of phosphatidyinositol (PI) 3-kinase. 
PI 3-kinase stimulates the production of phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3), which is known to modulate cytoskeletal rearrangement and it may 
be via this mechanism that wortmannin exerts its inhibitory effects (Arcaro and 
Wymann, 1993).
Thirdly, in neutrophils Jaconi et al. (1991) showed that integrin-mediated 
adherence and spreading stimulated the generation of [Ca2+]j transients, which 
were abolished in the presence of EGTA. Furthermore, cytochalasin B inhibited 
both adhesion and the generation of these [Ca2+]j transients. The requirement 
for extracellular Ca2+ for the spontaneous in human eosinophils, was 
demonstrated by the inhibitory effect of the Ca2+ chelating agent, EGTA.
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Moreover, human eosinophils loaded with the Ca2+-indicating fluorescent dye 
indo-1 , adhered and spread onto glass coverslips and spontaneous oscillations 
of [Ca2+]j were also observed (J. Schrenzel, personal communication).
The putative inhibitor of PLC-dependent processes, U73122, abolished the O2  
response, suggesting that release of intracellular Ca2+, via IP3  generation was 
involved. One possibility for the activation of PLC may be via tyrosine kinase 
activity, as it has previously been shown in Chinese Hamster Ovary cells 
transfected with m5 muscarinic receptors, that Ca2+-dependent tyrosine 
phosphorylation of PLCy is capaple of stimulating IP3  generation (Gusovsky et 
al., 1993). Furthermore, eosinophils are believed to possess PLCy, as it has 
recently be suggested that stimulation of degranulation responses in human 
eosinophils, by slgA-coated beads is mediated via tyrosine kinase and PLCy 
activation (Kato etal., 1995).
Investigation of the type of Ca2+ influx pathway(s) that may be present in human 
eosinophils was carried out using a range of agents with different 
pharmacological activities. The profile expected for a RMCE pathway is for Ni2+ 
and SK&F 96365 to be inhibitory, whereas VOC-blockers (e.g. nifedipine, 
diltiazem and verapamil) would have no effect (Benham etal., 1989).
Therefore, the spontaneous O2  response in eosinophils appeared to be 
dependent upon Ca2+ influx, via a receptor-mediated pathway, as SK&F 96365 
and the inorganic cation, Ni2+ blocked the response, whereas the VOC blockers 
nifedipine and diltiazem were without effect.
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SK&F 96365 is a useful tool for investigating Ca2+ influx pathways and has been 
used for distinguishing between different types of receptor-mediated Ca2+ influx 
channels, particularly in platelets and PC12 cells (Sargeant etal., 1992; Fasolato 
et al., 1990). SK&F 96365 is also known to have several non-specific effects, 
including blockade of potassium channels (Krautwurst etal., 1993; Schwarz et 
al., 1994) and cytochrome P-450 enzymes (Rodrigues etal., 1987). The lack of 
potent and selective inhibitors of RMCE necessitate the use of agents such as 
Ni2+ and SK&F 96365 when this influx pathway is investigated. However, careful 
interpretation of the data obtained with these inhibitors is required and it is 
necessary to compare the effects of several agents that modulate Ca+ influx, 
rather than considering each agent in isolation.
Simchowitz and Cragoe (1990) have previously suggested that chemotactic 
peptide-induced [Ca2+]j elevation and superoxide production in neutrophils, 
involves activation of Na+/Ca2+ exchange and that this is blocked by benzamil. 
Thus, the inhibitory effect observed with benzamil might suggest a role for 
Na+/Ca2+ exchange in this respiratory burst response. However, the 
overwhelming body of evidence from more recent studies suggests that fMLP 
stimulates receptor-mediated Ca2+ influx, via a store depletion-dependent 
mechanism and that this is the main route of Ca2+ entry in human neutrophils 
(Montero etal., 1991; Demaurex etal., 1994; Alvarez etal., 1994). These data 
therefore cast doubt upon the use of benzamil as a specific inhibitor of Na+/Ca2+ 
exchange.
NaF, which forms a complex with aluminium (AIF4") to stimulate heterotrimeric G
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proteins (Watson and Arkinsall, 1994), caused marked inhibition of the 
spontaneous release of 0 2. This suggests that an inhibitory G protein was 
activated, possibly Gs. Activation of Gs stimulates adenylyl cyclase activity, 
which leads to production of cAMP. Activation of PKA by cAMP has been shown 
to have an inhibitory effect on NADPH oxidase in human alveolar macrophages 
and thus inhibits 0 '2  release (Dent et al, 1994b). This hypothesis is valid, even 
though forskolin and salbutamol have no effect. It has previously been reported 
that although forskolin stimulates large increases in cAMP in most cell types, it 
is ineffective in guinea-pig eosinophils (Giembycz and Barnes, 1993). Moreover, 
it was suggested that this might possibly be due to a forskolin-insensitive form 
of adenylyl cyclase being present in these cells, or alternatively forskolin may be 
unable to cross the membrane of eosinophils.
The lack of effect observed with salbutamol is consistent with other groups who 
have investigated the effects of p-adrenoceptor agonists on the eosinophil 
respiratory burst response. Work carried out by Yukawa et al. (1990) 
demonstrated that p-adrenoceptors on eosinophils are functionally coupled to 
adenylyl cyclase. However, they also found that stimulation of p2-adrenoceptors 
by salbutamol did not inhibit the respiratory burst response in either guinea-pig 
or human eosinophils. Rabe et al. (1993) found that salbutamol caused some 
inhibition of H2 0 2  production in guinea-pig eosinophils, but only at relatively high 
concentrations (;>10'5 M). The lack of effect of the p-adrenoceptor agonists has 
been suggested to result from rapid uncoupling of the p-adrenoceptors from 
adenylyl cyclase (Giembycz and Barnes, 1993).
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Another possible mechanism of action for the inhibitory effects observed with 
NaF may be via inhibition of tyrosine kinase. In macrophages, NaF has been 
suggested to exert a direct effect on tyrosine kinase and this activity is unrelated 
to the formation of a complex with aluminium and an action on G proteins 
(Goldman and Zor, 1995). However, this seems unlikely, as subsequent 
experiments on the effect of NaF against fMLP-induced ECP release showed 
that the tyrosine kinase inhibitor, erbstatin analogue, but not NaF inhibited the 
response.
Finally, cyclosporin A (CsA) caused marked inhibition of the spontaneous 0~2 
generation in human eosinophils. CsA has also been reported to have a similar 
effect in human neutrophils, although the mechanism of action for this effect is 
not clear. CsA is known to interact with cyclophilin to form an active complex 
that inhibits calcineurin (PP2B), which is believed to be the mechanism of action 
for its immunosuppressive effects in T cells (Morley, 1992). However 
Cyclosporin H, which does not inhibit calcineurin, does inhibit the release of Oj 
in human neutrophils. This suggests that CsA inhibits O2  generation via a 
mechanism distinct from inhibition of calcineurin. It does not appear that CsA 
exerts its effects directly on the NADPH oxidase enzyme, as it was without effect 
in a cell-free oxidase system, which suggests that it may regulate the signal 
transduction process in some way (Wenzel-Seifert et al., 1991). However, the 
inhibitory effects observed in the neutrophil are not via inhibition of Ca2+ 
mobilisation, or via an effect on PKC (Wenzel-Seifert etal., 1991; Wenzel-Seifert 
etal., 1994).
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5.2 Effect of cytochalasin B on human eosinophils
The inhibition of adherence of eosinophils to microtitre plates by cytochalasin B 
was consistent with its known inhibitory effects on the assembly of actin 
(Bengtsson etal., 1991).
In this study, agonist-induced O* LTC4  and ECP release was measured in the 
presence of cytochalasin B, which appears to act as a priming agent. In the 
absence of cytochalasin B eosinophils produced little or no 0~2, LTC4  or ECP, in 
response to agonist (data not shown). This is consistent with work carried out 
by Takafuji et al. (1991) where they found that eosinophils required a priming 
agent before C5a-induced LTC4  release could be detected. Additionally, in 
agreement with the observations in this study, it has also been reported that a 
marked increase in ECP release is observed in the presence of cytochalasin B 
in response to either C5a (Takafuji et al, 1994) or fMLP (White et a l, 1993).
Cytochalasin B alone had little effect on the basal level of [Ca2+]j in human 
eosinophils. It also had no effect on C5a-induced IP3  generation or intracellular 
Ca2+ release. In contrast, it did cause a trend towards enhancement of the C5a- 
induced Ca2+ influx response. These observations show some similarity with 
data obtained by Treves et a l (1987), who investigated the effect of 
cytochalasins on [Ca2+]j in leukocytes. They found that cytochalasins alone 
caused some increases in [Ca2+]j and the extent of this effect varied depending 
on the cell type studied. Neutrophils responded with a marked transient
mobilisation of intracellular Ca2+, whereas lymphocytes exhibited a much smaller 
transient elevation of [Ca2 +]j. Furthermore, cytochalasin B enhanced the 
duration of the fMLP-induced Ca2+ mobilisation response in human neutrophils, 
via an effect on Ca2+ influx rather than on intracellular Ca2+ release.
Interestingly, Sedgwick et al. (1992) observed that fMLP-stimulated BAL 
eosinophils (i.e. primed cells) have a much greater Ca2+ influx and respiratory 
burst response than those taken from peripheral blood. This is particularly 
interesting as there is also evidence that eosinophils from atopic individuals have 
an enhanced LTC4  (Aizawa etal., 1990) and respiratory burst (Koenderman and 
Bruijnzeel, 1989) response, compared with those from normal individuals.
Cytochalasin B may act by increasing the percentage of cells in the population 
that respond to agonist (Daniels etal., 1994). This may be via increased surface 
expression of receptors, as a result of decreased internalisation of receptors in 
the presence of cytochalasin B (Bengtsson et al., 1991). In neutrophils it has 
been suggested that the prolonged [Ca2+]j transients reflect an increased fusion 
of specific granules with the plasma membrane. This causes new fMLP 
receptors, which are present on specific granule membranes, to be exposed on 
the outer surface of the cell (Treves et al., 1987).
5.3 Effect of Ca2+ modulation on human eosinophil activation
Using the Ca2+-chelating agent EGTA, it has been demonstrated in this study 
that C5a stimulates Ca2+ mobilisation responses which involve both release of 
Ca2+ from internal stores, via IP3  generation, as well as Ca2+ influx across the
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plasma membrane. Characterisation of the influx response using a range of 
Ca2+ channel blocking agents, suggests that Ca2+ influx occurs via a receptor- 
mediated entry pathway, as a result of emptying of intracellular Ca2+ stores. 
Furthermore, Ca2+ influx via a receptor-mediated pathway is required for C5a- 
and fMLP-induced O2  and LTC4 release.
Previously, Kernen et al. (1991) have reported that C5a stimulates a rise in 
[Ca2+]j. In the current study, C5a (30nM) caused the generation of IP3, which 
was maximal 5 seconds after agonist addition. U73122, an inhibitor of PLC- 
dependent processes, partially inhibited C5a-induced IP3 generation but 
abolished both the Ca2+ mobilisation and Mn2+ influx responses. In addition, both 
C5a- and fMLP-induced Oj production and LTC4 release were also blocked by 
U73122, but not by its inactive, analogue, U73343.
Smith et al. (1990) reported similar effects in human neutrophils against 
chemotactic peptide-mediated Ca2+ mobilisation and 0~2 release. Furthermore, 
fMLP-induced increases in [Ca2+]j were reported to be more susceptible to 
inhibition by U73122 than IP3 production. This discrepancy in potency was 
suggested to be due to non-cooperative binding of IP3 to its intracellular 
receptor. This binding results in highly co-operative opening of endomembrane 
Ca2+channels. Thus a small decrease in IP3 concentration may be sufficient to 
completely inhibit IP3-mediated release of intracellular Ca2+.
An alternative explanation for the decreased potency of U73122 against C5a- 
induced IP3 generation, compared with its effects against Ca2+ mobilisation, may 
result from differences in the cell concentrations for these assays. Measurement
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of [Ca2+]j was made using a concentration of 1x106 cells/ml, whereas IP3 
generation was assayed using 2-3x107 cells/ml. Bleasdale etal. (1990) reported 
a decrease in the potency of U73122 when the cell concentration was increased 
by 10 fold. This was suggested to occur as a result partitioning of U73122 into 
cell membranes, which would cause a reduction of the amount available for 
inhibition of PLC-mediated processes.
A report by Vickers (1993) suggested that U73122 may also have effects on 
phosphoinositide metabolism and so limit the usefulness of U73122 as a tool for 
evaluating PLC-mediated responses. However, the concentrations used in the 
latter study were much higher (15pM) than were used in either this study or that 
by Smith et al. (1990). It should also be stressed that in the current study, 
U73122 was used at a concentration that should not inhibit PLD-mediated 
effects (Naccache et al., 1993). In addition, the combination of measurement of 
IP3 generation, Ca2+ mobilisation and Mn2+ influx data, as well as the functional 
responses are consistent with a role for PLC in C5a-induced eosinophil 
activation, so it seems reasonable to interpret the effects of U73122 as acting 
against PLC-dependent processes in these experiments.
A rather surprising effect of U73122 was the observation that it inhibited 
thapsigargin-induced Ca2+ influx and LTC4 production. Rather conflicting results 
concerning the effect of U73122 appear in the literature. In rabbit pancreatic 
acinar cells U73122 was reported to have no effect on thapsigargin-induced Ca2+ 
influx (Willems et al., 1994), whereas in platelets it caused partial inhibition 
(Okamoto et al., 1995). The inhibitory effect observed in platelets was not via
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direct inhibition of Ca2+ influx, as the effect of an extract obtained from thrombin- 
stimulated platelets, which stimulates Ca2+ influx, was not inhibited by U73122 
(Okamoto etal., 1995). Similarly, in neutrophils stimulated with a cellular extract 
containing a factor which stimulates Ca2+ influx, U73122 inhibited the release of 
Ca2+ from intracellular stores, but not the influx response (Davies and Hallett, 
1995). Contrary to the effects reported in platelets and neutrophils, a study by 
Berven and Barritt (1995) in hepatocytes, found that U73122 and its 'inactive' 
analogue U73343 caused inhibition of Ca2+ influx directly.
The data obtained in this study would tend to suggest that U73122 exerted its 
inhibitory effects on thapsigargin-induced Ca2+ influx via an action on the release 
of intracellular Ca2+ from the stores. This was demonstrated by the observation 
that U73122 only inhibited thapsigargin-induced Ca2+ influx when added before 
thapsigargin but not afterwards. Thus, U73122 was unable to inhibit Ca2+ influx 
once store depletion had already taken place. In unstimulated cells it is possible 
that a basal level of PLC activation and IP3 generation is present. The action of 
IP3 on the receptors present on the endomembrane of intracellular Ca2+ stores, 
may cause the leak of Ca2+ into the cytoplasm (Favre et al., 1994). Normally, the 
endomembrane Ca2+/Mg2+-ATPase would replenish the Ca2+ stores, but in the 
presence of thapsigargin this would not occur. Thus the action of U73122 may 
be to prevent this 'leak pathway' and so prevent store depletion and activation 
of Ca2+ influx.
The peak increase in [Ca2+]j in response to C5a appeared to predominantly 
represent release of Ca2+ from intracellular stores. This was demonstrated by
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the removal of extracellular Ca2+, using the Ca2+ chelator EGTA, which had only 
a small inhibitory effect on the response. When the Ca2+ mobilisation response 
was analysed as an area under the curve, it was clear that EGTA had a similar 
effect during the first 30 seconds (AUC 0-30 seconds) after agonist addition as 
against the peak elevation in [Ca2+]|. In contrast, marked inhibition of the 
sustained response (AUC 30-100 seconds) was observed, suggesting that this 
predominantly represented the Ca2+ influx response. The inhibitory effects of 
EGTA against C5a and fMLP-induced O2  and LTC4 release appear to suggest 
that Ca2+ influx is required and that release of Ca2+ from intracellular stores alone 
is not sufficient to stimulate these functional responses.
Having established a role for extracellular Ca2+ for C5a-induced 0~2 and LTC4 
release in human eosinophils, the type of influx pathway that might be involved 
was investigated. The Ca2+ surrogate, Mn2\  was used to study the influx 
response. Measurement of Mn2+ influx has proved to be a useful technique 
when studying influx pathways (Merritt etal., 1989) as Mn2+ passes through Ca2+ 
channels and binds with high affinity to fura-2 (approximately 50 fold higher 
affinity than Ca2+; Grynkiewicz et al. (1985)) to quench its fluorescence. 
Furthermore, as Mn2+ would not normally be present in the cytosol, any quench 
in cytosolic fura-2 fluorescence can be directly attributed to the passage of Mn2+ 
ions across the plasma membrane. In addition, the C5a-induced concentration- 
effect curve when measured as AUC 30-100 seconds (which predominantly 
represented Ca2+ influx) correlated closely with the Mn2+ influx concentration- 
effect curve.
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Ca2+ influx can be stimulated by two main mechanisms, either by depolarisation 
of the plasma membrane, via voltage operated Ca2+ channels (VOCs), or via 
receptor-mediated Ca2+ entry (RMCE) pathways. VOCs are generally found in 
excitable tissue, whereas RMCE pathways are predominantly found in non- 
excitable cells (Meldolesi et al., 1991). The data obtained in this study are 
consistent with the presence of RMCE rather than VOC-mediated Ca2+ influx for 
several reasons. Firstly, the potent VOC-blocker nifedipine was without effect 
against C5a-induced Mn2+ influx at concentrations 300-1000 times higher than 
are normally required to block VOCs. Moreover, different chemical classes of 
VOC-blocker, namely the dihydropyridine nifedipine, the benzothiazepine 
diltiazem and the phenylalkylamine verapamil had little effect against C5a- and 
fMLP-induced 0~2 and LTC4 release. In contrast, depolarisation of the plasma 
membrane by KCI caused marked inhibition of these responses. This effect 
was presumably via inhibition of PLC activation and IP3 generation, which has 
previously been shown to be inhibited by plasma membrane depolarisation in 
HL-60 cells (Pittet eta l., 1990).
Secondly, Ni2+ and SK&F 96365, which inhibit both RMCE and VOCs, block the 
C5a-induced Mn2+ influx response. Furthermore, SK&F 96365 and a structurally 
related RMCE inhibitor, econazole, caused concentration-dependent inhibition 
of both C5a- and fMLP-mediated 0 2 and LTC4 generation. It was necessary to 
measure Mn2+ influx rather than AUC 30-100 seconds when assessing the 
effects of these agents against influx, as both SK&F 96365 and Ni2+ had effects 
on the basal [Ca2+1 measurements. Ni2+ caused a small quench of fura-2 
fluorescence upon addition to the cells. The kinetics of this effect would appear
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to suggest that this was due to entry of Ni2+ into the cells rather than quench of 
extracellular dye, particularly as this was not reversed upon addition of DTPA. 
In contrast, SK&F 96365 appeared to cause some elevation of [Ca2+]j when 
added to the cells. This is very similar to data obtained in human neutrophils, 
where SK&F 96365 caused some release of Ca2+ from intracellular stores as well 
as inhibition of Ca2+ influx (Merritt etal., 1990). An alternative explanation for the 
rise in [Ca2+]j caused by SK&F 96365 could be due to inhibition of Ca2+ extrusion 
from the cells, as it is known that a close analogue, SC 38249, has this activity 
(Ciardo and Meldolesi, 1990).
Thirdly, it has been reported that human neutrophils do not possess VOCs, but 
are believed to possess a single receptor-mediated Ca2+ entry pathway which is 
activated by depletion of intracellular Ca2+ stores (Demaurex et al., 1994). The 
data obtained in this study, using thapsigargin, demonstrate for the first time that 
human eosinophils possess a 'store-regulated' mechanism for controlling Ca2+ 
influx. In human eosinophils C5a caused PLC activation, leading to IP3 
generation and release and emptying of Ca2+ from intracellular stores. The 
concentration-effect curves for peak elevation of cytosolic Ca2+, AUC 0-30 
seconds, AUC 30-100 seconds and rate of Mn2+ influx were almost identical, 
which suggests that the degree of emptying of the Ca2+ stores may affect Ca2+ 
(Mn2+) influx (i.e. capacitative Ca2+ entry). Furthermore, the Ca2+ modulating 
agents show the same profile of effects against both C5a- and thapsigargin- 
induced increases in [Ca2+]j. In addition, the same inhibitors regulate the release 
of 0'2 and LTC4 in response to C5a and fMLP in an identical fashion to the 
inhibition of thapsigargin-induced LTC4 generation.
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The requirement for extracellular Ca2+for LTC4 production, in human eosinophils, 
is consistent with studies carried out by Wong et al. (1991) using rat basophilic 
leukaemic cells (RBL-2H3). Their studies showed that addition of EGTA to the 
extracellular medium inhibited the translocation of 5-lipoxygenase to the 
endomembrane and leukotriene synthesis. They also found that a sustained 
Ca2+ influx response was required for LTC4 generation.
Evidence for a fundamental requirement for a sustained Ca2+ influx response for 
LTC4 generation was the observation that thapsigargin stimulated LTC4 
generation, but did not cause O 2  or ECP release. Comparison of the 
concentration-effect curves for increases in [Ca2+]j and LTC4 generation, showed 
a marked difference in potency for the generation of these responses. The 
threshold concentration for LTC4 release was virtually maximally effective for 
[Ca2+]j elevation. This may suggest that a threshold level of [Ca2+]| elevation was 
required or alternatively, that an additional signal needs to be generated, before 
the formation of leukotrienes occurs.
In RBL-2H3 cells Wong et al. (1992) found that a threshold level of Ca2+ was 
required for leukotriene generation in response to thapsigargin or the Ca2+ 
ionophore, ionomycin. Interestingly, antigen-induced leukotriene release was 
also Ca2+-dependent, but required smaller increases in [Ca2+]j for an equivalent 
response to that obtained with ionomycin, suggesting that an additional 
pathway(s) was involved in the antigen-mediated response.
The extent of the thapsigargin-induced rise in [Ca2+]f was dependent upon 
whether store-depletion took place in the presence or absence of extracellular
145
Ca2+, but the potency remained the same. One possible explanation for this 
could be that a negative feedback process is activated when Ca2+ enters the 
cytosol, as has been found in adrenal chromaffin cells (Fonteriz et al., 1992). 
This could either be via a direct effect on the plasma membrane Ca2+ channels 
or possibly by inhibiting the generation of second messengers that are 
responsible for stimulating Ca2+ influx. Alternatively, in the presence of low 
[Ca2+]j levels, there may be decreased degradation of messenger(s) which 
stimulate Ca2+ influx (Randriamampita and Tsien, 1995). An interesting 
experiment, would be to investigate whether the concentration-effect curve for 
LTC4 generation is shifted to the left if a Ca2+ re-addition protocol is used, as well 
as comparing whether or not the threshold for generation of LTC4 correlates with 
the rise in [Ca2+]j.
Perhaps more surprising was the requirement for extracellular Ca2+ for 0~2 
release, in response to C5a and fMLP. PAF-induced O2  release in human 
eosinophils has been shown to be markedly inhibited, but not abolished, by 
EGTA (Zoratti et al., 1991). In contrast, generation of 0'2 in guinea-pig 
eosinophils in response to LTB4 (Subramanian, 1992) or PAF (Kroegel et al., 
1989b) has been reported to be independent of extracellular Ca2+. Despite 
differences in the Ca2+ requirements for 0~2 generation, an interesting similarity 
between the studies carried out using guinea-pig eosinophils and our study using 
human eosinophils is the separation between the concentration-effect curves for 
the Ca2+ responses and functional responses.
Many studies have been carried out on human neutrophils and the signal
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transduction pathways involved in the respiratory burst response. Generation 
of O 2  in the neutrophil can be mediated by at least two signal transduction 
sequences, involving both Ca2+-dependent and Ca2+-independent pathways 
which act in concert (Thelen et al., 1993; Wymann et al., 1995). It is possible 
that different agonists may vary in the degree to which they stimulate these 
pathways. In this study, it is clear that in human eosinophils extracellular Ca2+ 
is required for C5a- and fMLP-induced 0~2 and LTC4 release. However, the Ca2+ 
responses have a lower threshold and achieve a maximum effect at lower 
concentrations of C5a than are required for the functional responses. This 
suggests that although Ca2+ is required for these responses, other messenger(s) 
are also involved.
When measuring ECP release, it is clear that other signal transduction pathways 
must be activated by C5a and fMLP. C5a-induced ECP release appeared to be 
only partially dependent upon RMCE. Addition of U73122, KCI, SK&F 96365 or 
decreasing the extracellular [Ca2+] to 0.3mM caused approximately 50% 
reduction of the degranulation response. This suggests that although activation 
of PLC and Ca2+ influx were required for part of this response, another pathway 
that was independent of PLC activation and Ca2+ influx was also involved. This 
was even more evident when eosinophils were stimulated with fMLP. FMLP- 
induced ECP release was not inhibited by any of the Ca2+ influx blockers or by 
U73122.
5.4 Signal transduction in human eosinophils
Activation of human eosinophils by C5a and fMLP, was found to be mediated via
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a PTX-sensitive G protein(s). This is in agreement with the previous observation 
by Kernen etal. (1991) that C5a-induced EPO release and rises in [Ca2+]j were 
abolished by PTX pretreatment, although interestingly the shape change 
response was only partially inhibited. Additionally both C5a and fMLP have 
recently been reported to induce release of IL-8 and GM-CSF from cytochalasin 
B-treated eosinophils via a PTX-sensitive route (Miyamasu et al., 1995). 
Similarly, chemoattractant-mediated activation of neutrophils has also been 
shown to be via activation of PTX-sensitive G proteins (Becker et al., 1985; 
Becker et al., 1986; McDonald etal., 1991).
In this study, a close correlation was observed between PTX-mediated inhibition 
of the C5a- and fMLP-induced Ca2+ mobilisation response and the functional 
responses (LTC4 and/or ECP release). PTX acts by uncoupling Gr like 
heterotrimeric G proteins (mainly Gah, Gai2 and Gai3) from their receptor, by 
ADP ribosylating the a subunit (Watson and Arkinsall, 1994). Receptor- 
mediated activation of heterotrimeric G, proteins causes them to separate into 
their a and py components. Whilst the a subunit has an inhibitory effect upon 
adenylyl cyclase activation, it has been shown in neutrophils that the py subunit 
stimulates activation of PLCp (Watson and Arkinsall, 1994; Blank etal., 1992). 
Antibodies to the different sub-types of Gia are commercially available and could 
be used to identify which sub-type(s) of G^ may be present in human eosinophils 
and are activated by C5a and fMLP.
Despite the fact that both C5a and fMLP mediate their effects through a PTX- 
sensitive G protein, it was clear that there are major differences in the signal
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transduction pathways that regulate their functional responses. Schematic 
representations of the different signal transduction processes that appear to 
regulate C5a-induced LTC4 and ECP generation, as well as fMLP-induced LTC4 
and ECP release, are shown in figures 38, 39,40 and 41, respectively. It should 
be emphasised that these representations are both speculative and necessarily 
much simplified. They are mainly based upon the data obtained in this study 
and as such, only a limited range of agents have been tested. Clearly, it is 
necessary that other inhibitors, particularly of tyrosine kinase, PI 3-kinase and 
PLD are tested to confirm the data obtained in this study. Furthermore, 
biochemical measurement of the activity of these enzymes in eosinophils must 
also be made. However, it should also be stressed that these data are 
consistent with what is known about chemotactic peptide-induced activation in 
other cell types, particularly in the neutrophil.
The data obtained with the erbstatin analogue suggest that tyrosine kinase 
activity is extremely important for the generation of functional responses in 
human eosinophils, but does not appear to be involved in the Ca2+ mobilisation 
response. Similarly, it has previously been reported that stimulation of human 
eosinophils using Sepharose beads coated with secretory IgA or IgG, caused a 
degranulation response that was dependent upon activation of tyrosine kinase 
(Kato et ai, 1995). In common with these findings, there is a mounting body of 
evidence for a major role of tyrosine kinase in chemoattractant signalling in 












Schematic diagram of proposed signal transduction pathways that regulate C5a-induced ECP release, 
in human eosinophils.
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Schematic diagram of proposed signal transduction pathways that regulate fMLP-induced ECP release, 
in human eosinophils.
the increase in [Ca2+]j elicited by C5a or fMLP in human neutrophils, it decreased 
the level of tyrosine phosphorylation stimulated by fMLP and abolished the 
respiratory burst response. More recently, it has been suggested that G proteins 
play a major role in the coupling of chemoattractant receptors with tyrosine 
kinases and that this coupling occurs in parallel to PLC activation in neutrophils 
(Rollet etal. 1994).
C5a and fMLP have been shown to activate both PLC and PLD in cytochalasin 
B-treated neutrophils (Kessels etal., 1991; Kanaho etal., 1991; Mullmann etal., 
1990b). It is now believed that receptor-mediated activation of PLD can occur 
as a consequence of tyrosine kinase stimulation (Yasui etal., 1994; Uings etal., 
1992) and that protein phosphorylation by the kinase, increases the efficiency 
of coupling between the chemotactic peptide receptor and PLD (Garland, 1992). 
Naccache et al. (1993) found that wortmannin (*50nM) caused inhibition of 
tyrosine phosphorylation in neutrophils and that this was dissociated from its 
effects against PLD. They further suggest that the inhibition of PLD observed 
with wortmannin was as a direct consequence of inhibition of tyrosine kinase.
Stimulation of human eosinophils by C5a has been shown to cause activation 
of PLD (Minnicozzi et al., 1990). Thus, in human eosinophils, it remains to be 
seen whether the inhibition of the fMLP and C5a-induced ECP release, by 
wortmannin (1pM) was due to inhibition of tyrosine kinase or whether inhibition 
of subsequent PLD activation was the major pathway involved.
At low concentrations (<;10nM) wortmannin acts as a potent and specific inhibitor 
of PI 3-kinase (Arcaro and Wymann, 1993; Okada etal., 1994). In RANTES-
stimulated T lymphocytes, chemotaxis and polarisation responses were found 
to involve activation of PI 3-kinase (Turner et al., 1995). Similarly, activation of 
PI 3-kinase in neutrophils has been shown to be mediated via G protein-coupled 
receptors and is involved in acute activation of functional responses, particularly 
the respiratory burst response (Thelen etal., 1994; Ding etal., 1995; Vlahos et 
al., 1995). In contrast, a recent study by Perkins et al. (1995) found that PI 3- 
kinase was not involved in the LTB4-mediated respiratory burst response in 
guinea-pig eosinophils. The data obtained in this study suggest for the first time, 
in human eosinophils, that PI 3-kinase may be activated by C5a. Furthermore, 
this appears to be the first evidence that PI 3-kinase may be involved in the 
regulation of leukotriene generation.
Activation of PKC caused marked inhibition of both LTC4 release and ECP 
generation in human eosinophils. This effect was probably as a result of its 
known inhibitory activity against the LTC4 synthase enzyme (Ali et al., 1994; 
Kargman et al., 1994). In addition, activation of PKC has been shown to both 
enhance efflux of Ca2+ across the plasma membrane and inhibit Ca2+ influx in 
human neutrophils (McCarthy et al., 1989), which would also inhibit LTC4 
generation.
The paradoxical effect that both activation of PKC, by PMA and inhibition of 
PKC, by bisindolymaleimide caused a reduction in both C5a- and fMLP-induced 
ECP release, is difficult to explain. One possibility may be that different isoforms 
of PKC are affected by these agents and that these isoforms phosphorylate 
different target proteins in the signal transduction pathway. It is possible that
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PMA might stimulate PKC isoenzymes that are inhibitory for ECP release, 
whereas bisindolymaleimide could inhibit different isoenzymes of PKC that are 
stimulatory for ECP responses. Clearly, further investigation is required to 
identify which isoenzymes of PKC might be involved in the regulation of 
eosinophil activation.
Attempts to elevate cAMP levels using forskolin and the p2-adrenoceptor agonist 
salbutamol, had no significant effect on the C5a- and fMLP-induced functional 
responses. This was presumably for the same reasons that have previously 
been discussed for their lack of effect against spontaneous 0 2 release. In 
contrast, inhibition of the breakdown of cAMP, by the type IV cAMP PDE inhibitor 
rolipram, abolished both 0 2 and LTC4 generation in response to C5a. However, 
rolipram did not cause any inhibition of ECP release.
The inhibitory effect observed with the PDE IV inhibitor against 0 2 production is 
consistent with other reports on both guinea-pig and human eosinophils (Dent 
et al., 1994a; Barnette et al., 1995). However, the lack of effect of rolipram in 
this study against C5a-induced ECP release contrasts with its relatively potent 
effects against LTB4-induced ECP release in guinea-pig esoinophils (Souness 
et al., 1995). This may either reflect a species difference or may simply reflect 
differences between C5a- and LTB4-mediated signal transduction pathways. 
The latter seems likely as C5a, but not LTB4, has been shown to stimulate PLD 
and PI 3-kinase activation in eosinophils (Minnicozzi etal., 1990; Perkins etal., 
1995).
The type IV PDE isoenzyme is the predominant form of cyclic nucleotide activity
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in inflammatory cells, particularly in eosinophils (Torphy etal., 1994). Therefore, 
a great deal of interest is currently focused on PDE IV inhibitors and it is thought 
that these agents may have a useful therapeutic potential in the treatment of 
asthma (Giembycz and Dent, 1992).
Inhibition of serine/threonine phosphatases markedly suppressed both C5a- and 
fMLP-induced O2  and LTC4 generation, but not ECP release. Calyculin, which 
inhibits PP1 and PP2A, was more potent at inhibiting the functional responses 
than the more selective PP2A inhibitor, okadaic acid. Thus, it would appear that 
inhibition of PP1 may lead to prolonged phosphorylation of certain target proteins 
that would have an inhibitory effect on 0~2 and LTC4 generation.
The effects of these inhibitors may be explained by causing a prolonged 
phosphorylation response as a result of C5a- or fMLP-induced PKC activation. 
This effect has been shown in neutrophils, resulting in enhanced fMLP-induced 
0"2 release (Djerdjouri et al., 1995; Lu et al., 1992). Thus, enhancing the effect 
of PKC activation would cause inhibition of LTC4 generation.
The lack of effect of okadaic acid and calyculin against ECP release could also 
be consistent with an effect on prolonging PKC-mediated phosphorylation 
events. The previous observation that both activation and inhibition of PKC 
inhibits ECP release, may suggest that some isoforms of PKC may have an 
inhibitory effect on ECP release, whereas others may have a stimulatory effect. 
The effect of calyculin or okadaic acid would be to prolong all phosphorylations 
stimulated by PKC (both stimulatory and inhibitory), resulting in a net lack of 
effect against ECP release. Alternatively, inhibition of PP1 may exert some
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additional effect, which results in enhancement of agonist-induced ECP release.
This study has identified some of the signal transduction pathways that are 
involved in human eosinophil activation, with the main emphasis on classical 
signal transduction pathways, that are activated via heterotrimeric G protein- 
coupled receptors. However, recent studies in phagocytic cells have identified 
a major role for low molecular weight GTPases (LMWG) in the regulation of 
functional responses (Bokoch, 1995). LMWGs function as molecular switches 
that are regulated by their association with guanine nucleotides, such that the 
GTP-bound form is active and GDP-bound is inactive. LMWGs belong to the 
Ras superfamily, with 5 main sub-families comprising Ras, Rho, Rab, Arf and 
Ran (Bokoch, 1995).
It is now well established that Rac2 is required for the activation of NADPH 
oxidase (Knaus et al., 1991). In addition, Arf (ADP-ribosylation factor) has been 
found to regulate PLD activity in human neutrophils via a mechanism that is 
dependent on the generation of polyphosphoinositides (Whatmore etal., 1994). 
In human eosinophils, Rab1 was suggested to be involved in the process of 
degranulation (Aizawa et al., 1992). Thus, it seems likely that LMWGs are 
involved in regulating signal transduction processes and it remains to be seen 
what role they may have in the regulation of eosinophil activation.
In summary, C5a and fMLP stimulate activation of human eosinophils via PTX- 
sensitive G protein-coupled receptors. Both agonists stimulate both PLC- and 
PLD-dependent pathways and require activation of tyrosine kinase for the 
generation of O* LTC4 and release of ECP. However, C5a and fMLP appear to
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have differences in the signal transduction pathways used to generate a 
particular response (e.g. LTC4 release in response to C5a, but not fMLP, 
involves activation of PI 3-kinase). Moreover, stimulation of different responses 
by a particular agonist, involves different signal transduction pathways (e.g. C5a- 
induced LTC4 release, but not ECP release, requires activation of PI 3-kinase).
5.5 Characterisation of LTD4-induced increases in [Ca2+]j in human 
eosinophils.
Stimulation of human eosinophils with LTD4j caused increases in [Ca2+]j which 
involved both release of Ca2+ from intracellular stores and Ca2+ influx, since 
EGTA caused partial inhibition of the response. However, LTD4 did not cause 
any stimulation of the respiratory burst response or ECP release. This provided 
further evidence that, in addition to elevation of [Ca2+]jf other signal transduction 
pathways are also required for these responses.
Pretreatment of human eosinophils with PTX caused some inhibition of the 
LTD4-induced increase in [Ca2+]j, but did not have any effect on the Mn2+ influx 
response. Increasing the concentration of PTX did not lead to complete 
inhibition of the response, suggesting that a PTX-insensitive component was 
also present The finding that LTD4 mediated its effects via both PTX-sensitive 
and insensitive pathways was consistent with the data obtained in other cell 
types including differentiated HL-60 cells (Baud etal., 1987), U937 cells (Saussy 
etal., 1989) and epithelial cells (Sjolander etal., 1990).
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In common with the findings in the current study, it has also been shown that 
PKC activation markedly attenuates the [Ca2+]j response in U-937 cells (Pollock 
and Creba, 1990). The inhibitory effect of PMA may have been via heterologous 
desensitisation of LTD4 receptors, as has previously been reported (Crooke,
1990). It is possible that calyculin, which caused rather variable inhibition of the 
LTD4-induced Ca2+ mobilisation response, may have exerted its effects by 
prolonging the PKC-mediated phosphorylation events thereby causing some 
desensitisation of the response.
The observation that LTD4 and LTB4 did not cross-desensitise suggests that they 
act at different receptors, whilst LTC4 had very little effect (data not shown). The 
presence of LTD4 (now termed CysLT,; Watson and Girdlestone, 1995) 
receptors on human eosinophils may have implications for the therapeutic 
effects of both LTD4 receptor antagonists as well as LSIs. Until recently, it was 
believed that their major effect would be via inhibition of bronchoconstriction 
(Wensing etal., 1994; Dahlen etal., 1993). However, it has now been shown 
in vitro, that LTD4 acts as a potent chemotactic agent on human eosinophils and 
that this effect is blocked by the selective CysL^ receptor antagonist, SK&F 
104353 (Spada et al., 1994). In addition, inhalation of LTE4 stimulated the 
recruitment of granulocytes (predominantly eosinophils) into the airways mucosa 
of asthmatic patients (Laitinen et al., 1993). This suggests that sulphidopeptide 
leukotrienes may be involved in the inflammatory response associated with 
asthma.
160
5.6 Current/potential anti-asthma agents
With the current emphasis on the role of eosinophils and inflammation in asthma, 
it is pertinent to investigate whether any of the currently used anti-asthma and 
anti-inflammatory agents are capable of modulating the activation of human 
eosinophils.
Cetirizine has previously been reported to to have anti-allergic properties in 
addition to its H, antihistamine effects (Naclerio, 1991). In a study by Okada et 
al. (1994), cetirizine was reported to partially inhibit the respiratory burst 
response in eosinophils from allergic patients but not from normal donors, as 
well as inhibiting chemotaxis. However, in vivo cetirizine had no effect on either 
the early or late asthmatic response after allergen challenge (de Bruin-Weller et 
al., 1994). In this study, there was no evidence for an anti-inflammatory effect 
of cetirizine against either C5a- or fMLP-induced eosinophil activation.
The Katp channel opener, cromakalim, acts as a bronchodilator agent, although 
its therapeutic usefulness is limited by its cardiovascular side-effects (Nagai et 
al., 1991; McPherson, 1993). In this study, cromakalim was not found to have 
any effect on the generation of O* LTC4 or release of ECP in human eosinophils.
Sodium cromoglycate is believed to exert anti-inflammatory effects in addition 
to its mast cell 'stabilising' properties. It has been reported to inhibit 
inflammatory responses which are stimulated via IgE stimulation of FceRII, in a 
range of inflammatory cells (Tsicopoulos et al., 1988). It was also reported to 
inhibit ECP release from eosinophils stimulated with anti-IgG antibodies
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(Beauvais et al., 1989). In contrast, PAF- and LTB4-induced chemotaxis in 
human eosinophils was not inhibited by sodium cromoglycate (Bruijnzeel et al.,
1990). In this study, the release of O2 , LTC4 and ECP in response to the 
chemotactic peptides C5a and fMLP were not inhibited by sodium cromoglycate.
Neither the PAF antagonist, WEB 2086, or the cyclo-oxygenase inhibitor, 
indomethacin, caused any inhibition of fMLP-induced LTC4 or ECP release. 
However, both agents caused inhibition of C5a-induced LTC4 release but had no 
effect on ECP release. The effect of indomethacin is unlikely to be due to non­
specific inhibition of PLA2 as it would also have inhibited the fMLP-induced 
response. A speculative explanation for the effects of these agents against C5a- 
induced stimulation of eosinophils could be that C5a-stimulated the generation 
of PAF and prostanoids, which contributed to the effect of C5a on eosinophils 
via a paracrine- or autocrine-mediated mechanism. Therefore, it might be 
interesting to assay for the generation of PAF and prostaglandins, in these cells 
and also to test a selective thromboxane synthase inhibitor, to determine 
whether release of thromboxane was involved in this response.
BAY x1005 acts as a potent and selective inhibitor of leukotriene synthesis via 
inhibition of 5-lipoxygenase-activating protein (FLAP) (Hatzelmann etal., 1994). 
FLAP acts as a 'docking1 protein in the endomembrane and 5-LOX translocation 
to this site is essential for its leukotriene synthesis activity (Ford-Hutchinson,
1991). The data obtained in this study confirmed that BAY x1005 selectively 
inhibits LTC4 release from eosinophils and has no effect on ECP release.
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Furthermore, the presence of CysL^ receptors on human eosinophils, which are 
stimulated by LTD4 (a metabolite of LTC4) to produce chemotactic responses, 
may enhance the potential anti-inflammatory profile of leukotriene synthesis 
inhibitors.
5.7 Summarising Discussion
In conclusion, C5a stimulated increases in [Ca2+]j, comprising release of Ca2+ 
from intracellular stores, via PLC-mediated IP3 generation and Ca2+ influx across 
the plasma membrane, via a receptor-mediated Ca2+ entry pathway. 
Furthermore, receptor-mediated Ca2+ entry is required for production of O2  and 
LTC4 in response to both fMLP and C5a. In contrast, C5a-induced ECP release
appears to only be partially dependent upon RMCE, whereas the fMLP-induced 
response did not appear to require extracellular Ca2+.
The RMCE pathway in human eosinophils is probably regulated by depletion of 
intracellular Ca2+stores as intracellular Ca2+ release correlates closely with Ca2+ 
(Mn2+) influx. Furthermore, it is clear that human eosinophils possess such a 
mechanism for regulating Ca2+ influx, as the Ca2+/Mg2+ ATPase inhibitor, 
thapsigargin, stimulated a prolonged Ca2+ influx response.
Thus, Ca2+ influx appears to play an important role in regulating the activation of 
human eosinophils. Inhibition of Ca2+ influx would appear to be a potential 
strategy for the design of a therapeutic agent in asthma. In the light of the recent 
report that C5a and fMLP stimulate the release of IL-8 and GM-CSF from human 
eosinophils (Miyamasu etal., 1995), it would be extremely relevant to investigate
163
whether this process is dependent upon RMCE. Inhibition of cytokine generation 
from human eosinophils may help reduce the further recruitment of cells to the 
site of inflammation and this would certainly enhance the therapeutic potential 
of a RMCE inhibitor in asthma.
Currently, there are no potent and selective agents that are able to inhibit this 
influx pathway. An increased understanding of the regulatory mechanisms that 
control receptor-mediated Ca2+ influx in non-excitable cells, as well as 
determination of the molecular identity of this channel, is still required.
Randriamampita and Tsien (1993) were the first to partially characterise a novel 
soluble mediator, which was generated in response to depletion of intracellular 
Ca2+ stores and could be extracted from Jurkat cells. This messenger caused 
a sustained Ca2+ influx response when applied extracellularly to macrophages, 
fibroblasts and astrocytoma cells and was termed calcium influx factor (CIF).
However, since this initial report, several groups have attempted to purify this 
extract and determine the chemical identity of CIF, so far without success. 
Jurkat cell extract contains at least 2 factors that regulate Ca2+ influx activity. 
One of these factors is a polar molecule, which is only active intracellularly, 
whilst the other is non-polar and active when applied extracellularly (Thomas and 
Hanley, 1995). Attempts to activate lCRAC with Jurkat cell extracts have been 
reported to be unsuccessful, whilst activation of an unrelated non-selective 
cation channel has been reported (Clapham, 1995). Thus, it remains to be seen 
whether a pure CIF, which signals depletion of Ca2+ stores, will eventually be 
identified.
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More recent hopes for identifying a Ca2+-store-operated channel have focused 
on the Drosophila transient receptor potential (trp) Ca2+ channel. The Drosophila 
trp gene codes for a photoreceptor Ca2+ channel with properties analagous to 
those of lCRAc(Vaca et al., 1994).
Expression of trp protein in bacullovirus Sf9 insect cells demonstrated that this 
protein forms a channel that is highly Ca2+-permeable and is activated by 
thapsigargin (Vaca et al., 1994). Cloning of trp has recently lead to the 
identification of homologous proteins in Xenopus oocytes and mouse brain, 
which is the first evidence of a mammalian homologue of trp. Furthermore 
expression of trp in Xenopus oocytes lead to a significant increase in 
capacitative Ca2+ entry (Petersen etal., 1995). It is hoped that the identification 
of mammalian homologues of trp will potentially lead to the cloning of store- 
operated Ca2+ channels.
Thus many advances in the understanding of the regulation and function of 
RMCE have recently been made. It remains to be seen whether different sub- 
types of channel will identified, analagous to the situation with VOCs. The 
identification of potent and specific inhibitors of RMCE pathway(s) will also be 
of great value in characterising these channels and identifying whether there are 
different sub-types of channel.
The ubiquitous presence of these Ca2+ channels on inflammatory cells makes 
them an attractive target for modulation of inflammatory responses. Future 
potent RMCE inhibitors may represent a novel mechanism for a new class of 
anti-inflammatory agent. Furthermore, the regulatory effect of RMCE inhibitors
on human eosinophil activation suggests that this class of agent may represent 
an exciting new therapy for the treatment of asthma.
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